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ABSTRACT 
Background: Folate and choline are essential nutrients of particular importance 
during pregnancy and lactation and among nonpregnant women of reproductive age. 
However, in the era of folic acid (FA) fortification, high folate status and supplement 
use during pregnancy have been linked to adverse outcomes including asthma and 
eczema in children. No dose response studies conducted with women informed the 
choline Adequate Intakes (AIs), meanwhile evidence suggests that intakes greater than 
the current AI could optimize pregnancy endpoints. Research informing intake 
recommendations and strategies that promote optimal outcomes while avoiding 
inadequate and excessive intakes of folate and choline are needed.  
Objective: This research sought to quantify status and functional indicators of folate 
and choline metabolism in response to controlled intakes among pregnant, lactating, 
and nonpregnant women. 
Design: Pregnant (n=26), lactating (n=28), and nonpregnant (n=21) women 
consumed: a prenatal supplement containing 750 µg FA; 480 or 930 mg choline/d ; 
and 200 mg docosahexaenoic acid (DHA)/d for 10–12 wks. Biological samples were 
collected throughout the study. Folate status indicators were measured in all groups. 
 Phosphatidylcholine(PC)-DHA, a functional indicator of choline metabolism, was 
assessed in pregnant and nonpregnant women.  
Results: (1) At study-end, serum folate concentrations did not differ (P=0.876) by 
physiologic group and urinary folate excretion represented ~9–43% of intake. 
Breastmilk FA concentrations increased (P=0.003), while total folate remained 
constant (P= 0.244) over time.  
(2) PC-DHA was greater (P=0.01–0.001) among pregnant women at baseline. PC-
DHA increased (P<0.001) in both groups regardless of choline intake; however, 
among nonpregnant women, consumption of 930 mg choline/d led to greater 
(P=0.011) PC-DHA.  
Conclusions: (1) The study folate dose yielded supranutritional folate status in all 
physiologic groups. Given unresolved concerns about exposure to excess FA and the 
widespread folate adequacy of our FA-fortified population, it may be prudent to 
reduce the amount of FA in prenatal supplements.  
(2) Via its capacity to donate methyl groups, a higher choline intake may facilitate 
synthesis and delivery of DHA to peripheral tissues among nonpregnant women and 
increase availability of methyl groups during pregnancy. These beneficial endpoints of 
choline intakes greater than the current AIs warrant further exploration.  
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PREFACE 
Background 
Folate and choline are essential nutrients related to one another through one-
carbon metabolism (Figure P.1). Adequate folate and choline nutrition are protective 
of neural tube birth defects (NTDs) that form early in pregnancy (1,2); provide one-
carbon units for essential methyltransferae reactions; and are required for cell division 
(folate as a DNA precursor and choline as a component of phosphatidylcholine (PC), 
the membrane forming phospholipid). Thus, folate and choline nutriture are of 
particular importance during pregnancy and lactation and among nonpregnant women 
of reproductive age who may become pregnant.  
Folate Metabolism 
Folate refers to a group of related water soluble molecules with essential roles 
in nucleotide (purines and thymidylate) biosynthesis and amino acid metabolism. The 
primary form of folate in circulation is the reduced 5-methyltetrahydrofolate. Folic 
acid (FA) is a synthetic fully oxidized form of folate added to fortified foods and used 
in dietary supplements. Many forms of folate are enzymatically inter-convertible, 
although FA must be reduced to tetrahydrofolate in order to be utilized by the body 
(Figure 1) 
Folate Dietary Reference Intakes (DRIs) 
The Recommended Daily Allowance (RDA) is an intake value set to satisfy 
the nutritional needs of ~97% of individuals in a gender and life stage group. The 
Tolerable Upper Intake Level (UL) is a level above which there is increased risk of 
adverse effects. The folate RDAs are expressed as Dietary Folate Equivalents (DFEs) 
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to account for the greater bioavailability of FA versus naturally occurring food folate. 
The current folate RDA values for nonpregnant, pregnant, and lactating women are 
400, 600, and 500 µg DFEs/day, respectively (3). The folate RDAs for nonpregnant 
and pregnant women are based on intakes that maintain blood folate levels above 
adequacy cut-offs, while the RDA for lactating women adds the amount of folate lost 
through breastmilk to the RDA for nonpregnant women (3). The UL is 1000 μg 
FA/day which is related to the potential for excess folate intake to mask vitamin B12 
deficiency (3). Importantly, folate dose response studies have not been conducted with 
third-trimester pregnant or lactating women.  
    
Figure P.1 Folate and choline in one-carbon metabolism 
One-carbon methyl units (denoted by black dots) from 5-methyl-THFolate and choline, 
via betaine, are used to methylate homocysteine to methionine. Methionine is 
converted to S-adenosylmethionine, which participates in methylation reactions, 
including the methylation of PE to PC via the PEMT pathway.  
Abbreviations: 5-methyl-THFolate, 5-methyltetrahydrofolate; DMG, dimethylglycine; 
PE, phosphatidylethanolamine; PEMT, phosphatidylethanolamine N-
methyltransferase; PC, phosphatidylcholine; SAH, S-adenosylhomocysteine; SAM, S-
adenosylmethionine; THF, tetrahydrofolate 
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Folic acid exposure and neural tube defects 
Pre-conception FA supplementation reduces incidence of NTDs (1,4). The 
Centers for Disease Control and Prevention and Institute of Medicine (IOM) 
recommend that women of childbearing age consume 400 µg FA/day in addition to 
food folate from a healthy diet for the prevention of NTDs (3,5). To help women 
achieve FA intake goals and reduce NTD incidence, federally mandated FA 
fortification of enriched cereal grain products designed to deliver ~100 μg FA/day was 
implemented in 1998 (6). In addition to FA added to the food supply (i.e., fortified 
foods), the other important source of FA exposure is dietary supplements. Although 
FA-containing supplement use varies widely by ethnicity, education, and age, studies 
show ~38% of adult females and ≥80% of pregnant and lactating women, consume 
multivitamin supplements (7–9). Prenatal multivitamin supplements are produced 
specifically for and marketed to women of childbearing age and are generally labeled 
to contain 800–1000 μg FA, an amount that exceeds RDAs for all physiologic groups. 
Folate status in the era of folic acid fortification 
Since FA fortification was implemented, population wide folate status has 
improved dramatically: National Health and Nutrition Examination Survey 
(NHANES) data show that mean serum folate in females increased from 5.8 ng/mL 
pre-fortification to 14.1 ng/mL post-fortification (10). Improved folate status among 
women of reproductive age has reduced NTD incidence in the United States by19–
60% (11,12); however, putative effects of increased FA exposure have become an 
issue (13). High or supranutritional folate status, which is typically the result of FA 
supplement use (14), has been linked to cognitive impairment via high folate/low 
 xvi 
vitamin B12 imbalance and a purported “dual role” in cancer prevention and 
promotion (13). What is more, an emerging body of literature suggests in utero 
exposure to maternal supranutritional status and/or FA-containing supplement use is 
associated with adverse outcomes in children such as increased risk for asthma and 
eczema (15,16). 
The 1998 folate DRIs were based on studies executed before the advent of FA 
fortification and the accompanying increase in population wide folate status. In 
addition, high prevalence of FA-containing supplement use highlights this source of 
FA exposure among pregnant and lactating women. In order to refine folate intake 
guidelines going forward, controlled feeding studies measuring folate status that 
results from the consumption of a realistically achievable folate intake (e.g., folate 
from a mixed diet and over-the-counter FA-containing prenatal supplement) within the 
context of population wide folate sufficiency are warranted.  
Choline metabolism 
The essential micronutrient choline may be: (1) a source of one-carbon units 
via its oxidative product betaine; (2) a precursor of PC, the ubiquitous phospholipid; 
and/or (3) used to generate the neurotransmitter acetylcholine (Figure 1). The 
phosphatidylethanolamine N-methyltransferase (PEMT) pathway generates PC via the 
addition of three methyl units to the phosphatidylethanolamine (PE) molecule; thus 
PEMT is a PC biosynthetic pathway as well as the source of de novo choline synthesis 
in the body as free choline may be hydrolyzed from the PC molecule (Figure 1).  
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Choline Adequate Intakes 
The IOM publishes Adequate Intakes (AIs) when there is not enough evidence 
to establish RDAs. Although plasma choline decreases given a choline deficient diet, 
under normal conditions plasma choline is not well correlated with choline intake, in 
addition, folate, vitamin B12, and methionine status may impact plasma choline 
concentrations (3,17). Consequently, circulating levels of the liver enzyme alanine 
aminotransferase (ALT), an indicator of liver dysfunction, was used in setting the AI. 
Dose response studies conducted with women were not available for consideration 
when the choline AIs were published in 1998. Thus, the 425 mg choline/day AI value 
for nonpregnant women was based upon the amount required to prevent elevation of 
ALT in adult males (3). The 450 mg choline/day AI value for pregnant women added 
an increment of 25 mg choline/day to the nonpregnant AI to account for choline 
accretion of the fetus and placenta; this value was extrapolated predominately from 
animal data (3).  
Human and animal research suggests that there is increased demand for choline 
during pregnancy due to maternal metabolic needs associated with gestation as well as 
fetal development and accumulation (18). In addition, studies in animals show that the 
offspring of choline supplemented mothers have improved memory and protection 
against age related cognitive decline (19). Taken together this body of evidence 
indicates that the current AI for pregnant women, 450 mg choline/day, may not 
optimize outcomes for mothers or their babies.  
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Choline and lipid metabolism 
Choline metabolism is central to hepatic lipid metabolism as PC is required for 
lipoprotein formation and the export of triglycerides from liver. PC is composed of a 
three carbon chain linked to a phosphocholine head group and two fatty acids. Choline 
is a substrate of the CDP-choline pathway which synthesizes PC containing the 
unsaturated linoleic and oleic fatty acids (20) (Figure 1). In addition, methyl groups 
from the choline metabolite betaine may be used to generate PC via the PEMT 
pathway which produces PC enriched with polyunsaturated fatty acids (Figure 1). 
Notably, PC enriched with docosahexaenoic acid (DHA), a long chain polyunsaturated 
fatty acid with essential roles in human health throughout life , appears to be 
exclusively synthesized via PEMT (20). The use of plasma PC-DHA has been 
suggested as a proxy for assessing hepatic PEMT activity (21); however, it is unclear 
how a greater choline and/or DHA intake may influence flux through the PEMT 
pathway.  
PC is one of several phospholipids that make up cellular membranes and are 
used to form hepatic lipoproteins. Another important phospholipid is PE, which is also 
the precursor of PC formed through the PEMT pathway. Maintenance of the PC:PE 
ratio in cellular membranes has profound effects on membrane functionality (22,23); 
thus it is of interest to ascertain whether the increased demand for choline during 
pregnancy effects this ratio, and whether choline intake among pregnant and 
nonpregnant women influences erythrocyte and/or plasma PC:PE. 
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Functional indicators of choline metabolism 
The use of elevated liver enzymes, such as ALT, are useful indicator s of 
choline metabolism and status under conditions of choline deficiency; however, 
functional indicators of choline metabolism and status among healthy populations are 
still needed. It is clear that choline/betaine intake and DHA metabolism are linked 
through the PEMT PC biosynthetic pathway; perturbations in the relationship between 
methyl donors and polyunsaturated fatty acid metabolism have been noted in cystic 
fibrosis (24) and Alzheimer’s disease (25). In addition, the ratio of PC:PE also reflects 
choline metabolism as reductions in membrane and plasma PC:PE ratios have been 
associated with choline deficiency and impaired one-carbon metabolism (27,28). 
Nonetheless, how choline intake impacts erythrocyte and plasma PC-DHA and PC:PE 
ratios, i.e. functional indicators of choline metabolism, in healthy pregnant and 
nonpregnant women remains to be elucidated.  
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The Caudill Lab 
Research in the Caudill lab group investigates nutrient metabolism and 
requirement with the long term goal of optimizing intake recommendations. To this 
end, the Caudill lab conducted a12-week controlled feeding study with third-trimester 
pregnant women, lactating women 5–15 weeks postpartum, and nonpregnant women 
from January 2009 through December 2010 designed to answer pressing questions 
regarding folate and choline nutrition in these populations. The overarching aims of 
this study were: 
1. To elucidate how pregnancy and lactation influence folate and choline 
metabolism. 
2. To determine whether a choline intake greater than the current AI 
confers benefit to third trimester pregnant women and their babies, 
lactating women and their babies, and/or nonpregnant women of 
childbearing age. 
Within these broad aims, my dissertation research consisted of two projects 
with the following specific aims and hypotheses: 
Project 1: Folate status response to a controlled folate intake among nonpregnant, 
pregnant, and lactating women 
 Specific Aim:  To quantify folate status response to a known dose of folate comprised 
of a prenatal supplement containing 750 µg FA plus natural food folate (~400 μg 
DFEs) in third-trimester pregnant women, lactating women 5–15 weeks postpartum, 
and nonpregnant women of childbearing age. 
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Hypotheses: 
1. Mean serum folate concentrations will exceed the “high” folate status cut-off 
in all groups. 
2. Demand for folate will be greater in third-trimester pregnant and lactating 
women as evidenced by lower serum or RBC folate concentrations and/or 
lower urinary folate excretion. 
Significance and Innovation 
With implications for fetal development (with respect to NTDs) as well as 
healthy aging (with respect to cancer risk), proper folate nutrition is essential for 
optimal health. This study is significant because it will inform future folate intake 
guidelines by longitudinally assessing folate status among third-trimester pregnant, 
lactating, and nonpregnant women consuming a readily generalizable folate intake i.e., 
folate from a mixed diet and over-the-counter FA-containing prenatal supplement. 
This study is innovative because it will be the first that includes participants 
representing all three physiologic stages, i.e. non-pregnancy, pregnancy, and lactation, 
consuming an identical folate dose, which allows straight forward comparison of 
folate status, utilization, and requirement. 
Project 2: The influence of choline intake and pregnancy on phosphatidylcholine 
docosahexaenoic acid enrichment among third-trimester pregnant and nonpregnant 
women 
Specific Aims: (1) To determine whether choline intake influences erythrocyte and 
plasma PC-DHA and the PC:PE ratio among third-trimester pregnant and nonpregnant 
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women, and (2) To characterize the impact of pregnancy on erythrocyte and plasma 
PC fatty acid constituents and PC:PE. 
Hypotheses: 
1. A higher choline intake will increase PC-DHA in erythrocytes and plasma. 
2. A higher choline intake will increase the PC:PE ratio in erythrocytes and 
plasma. 
3. Erythrocyte and plasma fatty acids constituents and the PC:PE ratio will differ 
between pregnant and nonpregnant women, with greater PC-DHA 
concentrations and lower PC:PE ratio found among pregnant women. 
Significance and Innovation 
The study of choline metabolism as it relates to maternal and fetal outcomes is 
an emerging field. Dose response studies conducted with women of reproductive age 
are necessary for the refinement of choline intake recommendations that optimize the 
health of women and their children. This study is significant because it will inform 
future choline intake recommendations for understudied populations, i.e. pregnant and 
nonpregnant women, by quantifying response in third-trimester pregnant and 
nonpregnant women consuming two choline intakes: 480 mg choline/day, an amount 
approximating the current choline AI for pregnant women; and 930 mg choline/day, 
an amount roughly double the current AI for pregnant women.   
There is not a strong relationship between choline intake and plasma choline 
levels, thus other functional indicators of choline metabolism, utilization, and 
requirement are needed. This study is innovative because it explores the use of 
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erythrocyte and plasma PC-DHA and PC:PE ratio as functional indicators of choline 
metabolism in a population of great interest, women of reproductive age.  
Summary 
 These projects ask questions that will provide information for refining folate 
and choline intake recommendations and guidelines as well as provide insight into 
folate and choline metabolism among pregnant, lactating, and nonpregnant women. 
This work yielded two original research manuscripts (Chapters 1 & 2) and one 
methodological short communication (Chapter 3); in addition, I authored a review 
paper on the implications of genetic variation on folate and choline bioefficacy 
(Appendix A). Please enjoy the fruits of my labor! 
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CHAPTER 1 
Folate status response to a controlled folate intake among nonpregnant, pregnant, 
and lactating women
1
 
 
ABSTRACT 
Background: Folate dose response studies with women of childbearing age 
consuming a folic acid (FA)-containing multivitamin in the era of FA fortification are 
lacking. 
Objective: We sought to investigate folate status response to a known folate dose 
comprised of a FA-containing prenatal supplement plus natural food folate among 
third-trimester pregnant women, lactating women 5–15 wks postpartum, and 
nonpregnant women.  
Design: Pregnant (n = 26), lactating (n = 28), and nonpregnant (n = 21) women 
consumed the study folate dose under controlled intake conditions for 10–12 wks. 
Blood, urine, and breastmilk were collected at baseline, study-midpoint, and study-
end. 
Results: Study-end serum total folate concentrations averaged ~30 ng/mL and did not 
differ by physiologic group (P= 0.876). Study-end urinary folate excretion represented 
~9–43% of total folate intake and ranged from 100–500 µg/day. Third-trimester 
pregnant women excreted less urinary folate than lactating (P= 0.075) and 
nonpregnant (P< 0.001) women. Lactating women excreted less (P< 0.001) urinary 
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FA than nonpregnant women. Breastmilk total folate concentrations remained constant 
(P= 0.244; 61.8 ng/mL at study-end), while breastmilk FA concentrations increased 
(P= 0.003) to 24.1 ng/mL at study-end. 
Conclusions: Consumption of the study folate dose yielded supranutritional folate 
status regardless of physiologic state. Based on urinary folate, folate requirements 
were: pregnant > lactating > nonpregnant women. Breastmilk folate species were 
responsive to maternal folate intake with FA making up ~40% of breastmilk total 
folate at study-end. These findings warrant revisiting prenatal supplement FA 
formulation in populations exposed to FA fortification programs. 
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INTRODUCTION 
Folate refers to group of related molecules with essential roles in cellular 
methylation, nucleotide biosynthesis, and amino acid metabolism. Folic acid (FA) is a 
synthetic oxidized form of folate added to fortified foods and used in dietary 
supplements. In contrast, the majority of natural food folate is reduced, has a 
polyglutamate tail, and is ~40% less bioavailable than FA. In the U.S., folate 
requirements are met through natural food folate, FA-fortified foods, and folate/FA-
containing vitamin supplements (1). To account for differences in bioavailability, 
folate recommended intakes are given in dietary folate equivalents (DFEs) where 1 µg 
natural food folate and 1 µg FA are equivalent to 1 DFE and 1.7 DFEs, respectively 
(2).  
Pregnancy and lactation increase the demand for folate; current RDAs for 
nonpregnant, pregnant, and lactating women are 400, 600, and 500 DFEs/day, 
respectively (2). The Institute of Medicine and Centers for Disease Control and 
Prevention also recommend that women of child-bearing age consume 400 µg FA/day 
in order to decrease the incidence of neural tube birth defects (NTDs) (2,3). In 1996 
the Food and Drug Administration mandated that enriched grain products be fortified 
with FA to facilitate achievement of this recommended intake (4). As a result of FA 
fortification, folate status among women of childbearing age has dramatically 
improved (5) and incidence of NTDs has decreased 19–50% (6,7). 
Multivitamins are the most common dietary supplement consumed in the U.S 
(8). Most multivitamins contain 400 µg FA; however, prenatal multivitamin 
supplements often contain 800–1000 µg FA (9). Women of childbearing age are 
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advised to consume 400 µg FA per day through a combination of FA-fortified food 
and supplements (2); however, no explicit public health recommendation for healthy 
pregnant or lactating women to consume FA-containing supplements currently exists 
(10).  
NHANES 2003–2006 data and Gallup polling for the March of Dimes indicate 
30–38% of women of childbearing age consume FA-containing 
supplements/multivitamins (8,11).  Studies have found that 77–93% of pregnant (12–
14) and 73% of lactating (14) women use multivitamins; however, accurate prevalence 
is unknown among lactating women as this estimate does not come from a nationally 
representative study (10).  
Folate dose response studies are lacking in third-trimester pregnant and 
lactating women. In addition, there has not been a comprehensive longitudinal 
assessment of folate status achieved by women of childbearing age consuming an 
over-the-counter FA-containing prenatal supplement in the era of FA fortification. 
This study sought to quantify folate status response to a known dose of folate 
comprised of a FA-containing prenatal supplement plus natural food folate (~400 μg 
DFEs) in third-trimester pregnant women, lactating women 5–15 weeks postpartum, 
and nonpregnant women of childbearing age.  
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STUDY PARTICIPANTS AND METHODS 
Study Participants 
Nonpregnant, third trimester pregnant (27 weeks gestation), and lactating 
women 4 weeks postpartum aged ≥ 21 y were recruited from the Ithaca, NY area from 
January 2009–October 2010 as described by Yan et al. (15). During the screening 
stage, interested women provided a blood sample for blood chemistry profiling and a 
complete blood count. In addition, these women completed a health history and 
demographics questionnaire (see Appendix B for questionnaires). Important inclusion 
criteria for all participants were: (i) general healthiness as determined by the 
questionnaire, blood chemistry profile, and complete blood count; (ii) no drug or 
alcohol use; (iii) normal kidney and liver function; and (iv) willingness to comply with 
study protocol, i.e., eating a certain number of meals at the on-site location and not 
consuming food or beverages outside what was provided by the study. Additional 
inclusion criteria for pregnant women included: singleton pregnancy and no pregnancy 
associated complications, e.g., preeclampsia, gestational diabetes. Additional criterion 
for lactating women was the intention to exclusively breastfeed for the duration of the 
study. Exclusion criteria included: inability to comply with study protocols and use of 
prescription medications known to affect liver function. Eligible pregnant women 
were admitted to the study on a rolling basis at 26–29 weeks gestation; eligible 
lactating women were admitted to the study on a rolling basis at the start of 5 weeks 
postpartum; and eligible nonpregnant women were added as scheduling and space 
constraints allowed until the desired number of participants completed the study. 
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The study protocol was reviewed and approved by the Institutional Review 
Board for Human Study Participant Use at Cornell University and at the Cayuga 
Medical Center (the hospital where pregnant participants delivered their babies; 
Ithaca, NY). Study participants were compensated for participation and informed 
consent was obtained from all participants prior to their entry into the study (see 
Appendix B for informed consent documents).  
Study Design, Diet, and Supplements 
Design 
This study was an extension of a controlled feeding study conducted in 
pregnant, lactating, and nonpregnant women randomized to 480 or 930 mg 
choline/day for 10–12 weeks (15). Throughout the controlled feeding period (10–12 
weeks), all participants consumed an over-the-counter prenatal multivitamin 
supplement containing 750 µg FA daily, plus natural food folate (~400 µg) from a 
mixed diet. Nonpregnant and pregnant women participated in the controlled feeding 
study for 12 weeks, whereas, lactating women participated in the study for 10 weeks. 
Biological samples including blood, urine, and breastmilk were collected at baseline, 
study-midpoint (week 6), and study-end (week 10/12).  
Diet 
The study diet, as previously described (15), provided ~2000 kcal/day; 
however, participants could individualize their caloric intake by choosing to consume 
more or less of menu items and foods containing < 5µg folate per serving, such as 
unenriched rice, select juices and sodas, chips, and pudding (see Appendix B for study 
diet). Nonpregnant and pregnant women consumed meals on at least 5 days/week of 
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their choosing in the Francis A. Johnston and Charlotte M. Young Human Metabolic 
Research Unit (HMRU) at Cornell University. Lactating women consumed meals on 
at least 3 d/week of their choosing on-site in the HMRU. All other food and beverages 
were provided as take-aways.  
To control FA intake, commercial items manufactured without FA (e.g., whole 
wheat bread and organic specialty pasta) were utilized and menu items prepared in the 
HMRU (e.g., pizza dough and muffins) used unenriched wheat flour. Thus, dietary 
folate intake was restricted to naturally occurring forms with the only source of FA 
being the study prenatal supplement. 
Supplements 
 Each day study participants consumed an over-the-counter prenatal 
supplement (Pregnancy Plus®, Fairhaven Health, LLC, Bellingham, WA).  Although 
this prenatal supplement was labeled to contain 600 μg FA per tablet, the measured 
amount was 750 µg FA (see analytic measurements for details on methodology) and is 
the value used throughout this manuscript.  To achieve recommended nutrient intake 
levels not met with the study diet, study participants consumed also consumed a daily 
200 mg docosahexaenoic (DHA) supplement (Neuromins, Nature’s Way Products, 
Springville, Utah) (16) and a thrice weekly potassium/magnesium supplement 
(General Nutrition Corp., Pittsburgh, PA) . When eating on-site, participants 
consumed supplements under the supervision of study personnel. For days when study 
participants did not eat on-site, supplements were provided in baggies along with their 
take-away meals. Participants were instructed to consume the supplements with a meal 
of their choice.   
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Compliance 
The study protocol was well-tolerated with 91% of enrolled participants 
completing the study (21 of 22 nonpregnant, 26 of 29 pregnant, and 28 of 31 lactating 
women). Reasons for stopping the study included nausea, early delivery, personal 
challenges, and food dislikes (15).  
Study participants completed daily checklists indicating they received and 
consumed all menu items and supplements. For meals consumed onsite, study 
personnel were able to directly monitor compliance. For meals consumed off-site, 
participants were asked to return all empty baggies and take-away food containers to 
study personnel during their next visit to the HMRU. In addition, study personnel had 
daily contact with participants throughout the study to maintain positive rapport and 
enhance compliance. 
Sample Collection and Processing 
Blood: Fasting venous blood was drawn at baseline (all participants), study 
week 6 (all participants), study week 10 (all participants), and study week 12 
(nonpregnant and pregnant participants) in the HMRU ward by a trained phlebotomist. 
Blood samples were collected in EDTA and serum separator tubes, processed within 2 
hours, and stored in cryostat tubes at -80 
o
C until analysis as previously described 
(15). Ascorbic acid (10 g/L) was added to whole blood and serum samples during 
processing to preserve labile folates. 
Urine: Participants completed 24-hour urine collections at baseline (all 
participants) and study weeks 6 (all participants), 9 (nonpregnant and pregnant), 10 
(lactating), and 12 (nonpregnant and pregnant) in acid-washed opaque 2 L bottles as 
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previously described (15). To preserve labile urinary folates, 5 g sodium ascorbate was 
added to each bottle ahead of collection.  
Breastmilk: Breastmilk samples were collected at baseline and study weeks 6, 
9, and 10 with a Medella® electric breast pump in the HMRU. Lactating women were 
fasted for breastmilk sample collection which occurred on the same morning as the 
corresponding week’s blood collection. Breastmilk samples consisted of the full 
expression of one breast 2 hours after the first feed of the day. Women expressed the 
same breast throughout the study. Upon collection, the breastmilk samples were 
immediately placed on ice, dispensed within 30 minutes of collection into 4.5 mL 
cryostat vials (Cryo; NUNC, Roskilde, Denmark), and stored at -80
o
C until analysis. 
Analytic Measurements 
Food and breastmilk folate extracts 
Natural food folate provided by the study menu (dietary folate) and breastmilk 
folate concentrations were quantified from extracts prepared using the trienzyme 
method. Blank extracts were prepared from extraction buffer subjected to trienzyme 
digestion in order to quantify folate in enzyme preparations. All incubations were 
performed at 37 
o
C. 
For dietary folate extraction, prepared study meals were homogenized with 
cold 0.1 M potassium phosphate buffer with 57 mM ascorbic acid and stored at -80 
o
C. 
Upon thawing, meal samples (2 g) were mixed with extraction buffer (0.05 M CHES, 
0.05 M HEPES, 0.1 M sodium ascorbate, 0.2 M 2-mercaptoethanol) and subjected to 
trienzyme digestion as described by Tamura et al. (17). After digestion, sample 
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extracts were filtered through Whatman paper, and stored at -80 
o
C until 
quantification.  
Breastmilk sample extractions were prepared by the method of Lim et al. (18) 
with the following modifications. First, samples were mixed with 10 mg/mL sodium 
ascorbate and extraction buffer upon thawing. Second, after protease inactivation, pH 
was adjusted to 7.2 and samples were incubated for 5 hours with rat plasma conjugase 
(500 μL/mL breastmilk). Finally, following conjugase incubation, samples were 
centrifuged at 4
oC, filtered with 0.45 μm syringe filters (MillexHV), and stored at -80 
o
C. Breastmilk extracts for liquid chromatography-tandem mass spectrometry (LC-
MS/MS) and microbiological assay (MA) quantification were prepared separately. A 
stable-isotope internal standard (IS) mix was added to breastmilk before enzyme 
digestion for samples destined for LC-MS/MS quantification. Extracts for LC-MS/MS 
and MA methods were prepared from 4 mL and 0.1 mL breastmilk, respectively  
Microbiological assay measurements 
The MA method (19) with Lactobacillus casei (ATCC 7469) as the test 
organism and10 ng/mL FA (Sigma) as the standard calibrator was used to determine 
total folate concentrations in serum, whole blood, urine, breastmilk, and dietary folate. 
The coefficients of variance (CVs) were calculated using a positive quality control 
sample of each analyte, i.e. repeated measurement of a sample with the same matrix as 
the study biological samples being measured. The purpose of the positive quality 
control sample was to ensure that the assay and calibrators were working correctly and 
to determine the precision of the assay. MA intra-assay CVs were < 10%. MA inter-
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assay CVs were as follows: serum, whole blood, and breastmilk, < 10%; urine and 
dietary folate, < 13%.  
Red blood cell (RBC) folate values for nonpregnant and pregnant women were 
calculated from whole blood folate concentrations, serum total folate concentrations, 
and hematocrit values. Lactating serum folate was not measured via MA; serum 5-
methyl-THF + FA measured via LC-MS/MS was used a proxy for serum total folate. 
Dietary folate was determined twice, the first using meal extracts prepared 
before the start of the study and the second using meal extracts prepared during the 
study. Dietary and breastmilk folate values were corrected for exogenous folate (i.e. 
folate from amylase and/or conjugase preparations added during trienzyme digestion) 
by subtracting blank extracts MA values.  
LC-MS/MS measurements 
5-methyltetrahydrofolate (5-methyl-THF) and FA were quantified in serum, 
urine, and breastmilk using liquid chromatography-tandem mass spectrometry (LC-
MS/MS) stable-isotope dilution methods. Serum, urinary, and breastmilk extracts were 
prepared using solid phase extraction (SPE) clean-up methods on a 12-port vacuum 
manifold (J.T. Baker, Inc.). Extract eluents were concentrated with a SpeedVac 
centrifuge under vacuum with no heat before injection.  
Standard curves were prepared from 5-methyl-THF (Sigma) and FA (Sigma) 
stock solutions as described in Pfeiffer et al. (20). National Institute for Standard and 
Technology (NIST) standard reference materials, SRM 3280 (multivitamin tablets) 
and SRM 1955 (homocysteine and folate in frozen human serum), were used to 
validate the accuracy of FA and 5-methyl-THF calibrator curves, respectively. Internal 
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standard (IS) solutions were prepared using 
13
C-5-methyl-THF and 
13
C-FA (Merck 
Eprova, Switzerland) as described in Pfeiffer et al. (20). CVs were calculated using 
positive quality control samples included with each extraction batch. Extraction 
batches included all time points (i.e. baseline, week 6, and study-end) for 4–10 
participants. Details specific to the extraction method for each biological material are 
detailed below. 
Serum: 5-methyl-THF and FA were extracted from 400 μL of serum using the 
SPE clean-up method of Pfeiffer et al. (20). Serum 5-methyl-THF and FA were 
quantified via LC-MS/MS (20) with modifications based on our instrumentation. The 
LC-MS/MS system used to quantify serum folates was a TSQ Quantum mass 
spectrometer (Thermo, San Jose, CA) equipped with a refrigerated Accela 
autosampler (Thermo) and Accela pump with degasser (Thermo). 5-methyl-THF and 
FA were separated with a Luna C18 column (250 x 4.6 mm, 5 µm bead size; 
Phenomenex) and matching guard column (4 x 3 mm) using a gradient mobile phase 
(500 µL/minute) consisting of solution A (10 mL/L acetic acid, 400 mL/L methanol, 
100 mL/L acetonitrile) and solution B (0.15% formic acid). During the first 7 minutes 
of the run, a linear gradient brought the mobile phase from 50% to 100% solution A. 
This was followed by a linear gradient that returned the mobile phase to 50% solution 
A at minute 12. From minute 12 to minute 15 the column was re-equilibrated under 
isocratic conditions with 50% solution A. The retention times for 5-methyl-THF and 
FA were 5 and 9 minutes, respectively. The mass spectrometer was operated with 
electrospray ionization in positive ion mode with multiple reaction monitoring mode 
of the following transitions: 5-methy-THF, m/z 460→313; 13C-5-methyl-THF, m/z 
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465→313; FA, m/z 442→295; 13C-FA, 447→295. The total run time was 15 minutes, 
the injection volume was 15 µL, and the autosampler and column temperatures were 
set at 10
o
C and 25
o
C, respectively. Intra- and inter-assay CVs were 3.3 and 3.9%, 
respectively for serum 5-methyl-THF, and 8.5 and 13.7% for serum FA. 
 Due to the limited availability of ascorbic acid preserved serum (400–500 µL) 
and small amount of FA present, a limit of detection (LOD) and a limit of 
quantification (LOQ) were defined. Using serially diluted serum samples and a noise 
to signal ratio of 15 the serum FA LOD was set at 0.075 ng/mL. The intra-assay CV 
for samples < 0.11 ng/mL was 19.2%, whereas, the CV for samples with 
concentrations > 0.11 ng/mL was 8.5%; thus the serum FA LOQ was set at 0.11 
ng/mL. 
Urine: 5-methyl-THF and FA were extracted from 3 mL urine using an 
adaptation of the phenyl SPE method of Pfeiffer et al. (20). Briefly, urine samples 
were spiked with 
13
C-5-methyl-THF and 
13
C-FA IS preparation and mixed with 3 mL 
sample buffer (10 g/mL ammonium formate, 1 g/L ascorbic acid). Each sample was 
brought to pH 2.9 and allowed to equilibrate for 20 minutes at 20
o
C. Urines and 
calibrator points were cleaned up with 1 mL phenyl cartridges (100 mg; Bond Elut 
C18; Agilent) conditioned with 2 mL each of acetonitrile, methanol, and sample buffer 
(pH 2.9). After samples were loaded, cartridges were washed with 3 mL wash buffer 
(0.5 g/L ammonium formate, 0.05 g/L ascorbic acid; pH 3.4) and folates were eluted 
with 500 μL elution buffer (400 mL/L methanol, 100 mL/L acetonitrile, 10 mL/L 
acetic acid, 1 g/L ascorbic acid).  
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The LC-MS/MS Ion trap system used to quantify urinary folates consisted of a 
LCQ Advantage Max mass spectrometer (Thermo) equipped with a refrigerated 
Surveyor autosampler (Thermo) and Surveyor pump with degasser (Thermo). Urinary 
5-methyl-THF and FA were separated using the same column and gradient system as 
serum folates described above. The retention times for 5-methyl-THF and FA were 5 
and 8 minutes, respectively. The mass spectrometer was operated with electrospray 
ionization in negative ion mode with full scan parameters monitoring the following 
transitions: 5-methy-THF, m/z 458→329; 13C-5-methyl-THF, m/z 463→329; FA, m/z 
440→311; 13C-FA, 445→311. The total run time was 15 minutes, the injection volume 
was 10 µL, and the autosampler and column temperatures were set at 10
o
C and 25
o
C, 
respectively. Intra- and inter-assay CVs were 7.3 and 10.1%, respectively for urinary 
5-methyl-THF, and 10.4 and 11.6% for urinary FA. 
Breastmilk: 5-methyl and FA were extracted from 4mL breastmilk using a 
strong anion exchange (SAX) SPE clean-up method based on those of Vishnumohan 
et al. (21) and Friesleben et al. (22). Briefly, trienzyme digested breastmilk extracts 
with 
13
C-5-methyl-THF and 
13
C-FA IS as described above were adjusted to pH 7.5 
and cleaned up with 3 mL SAX cartridges (500 mg; Bond Elut SAX; Agilent) 
conditioned with 3 mL each of hexane, methanol, and MQ water; and 10 mL 
conditioning solution (0.01 M potassium phosphate, 0.1% ascorbic acid, 0.01% 2-
mercaptoethanol; pH 7.5). After samples were loaded, cartridges were washed with 3 
mL conditioning solution and folates were eluted with 1 mL elution buffer (5% 
sodium chloride, 1% sodium ascorbate, 0.1 M sodium acetate; pH 5.4).  
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Breastmilk folates were separated and quantified using the same Luna column 
and LC-MS/MS system as for serum folates described above. However, the mobile 
phase had to be modified in order to wash SAX elution buffer salts from the 
breastmilk extracts (22). Following 10 minutes of isocratic 7% solution A, a 3-minute 
linear gradient brought the mobile phase to 13% solution A. Then a 4-minute linear 
gradient brought the mobile phase to 30% solution A, followed by a second 4-minute 
linear gradient that brought the mobile phase to 90% solution A. A third 4-minute 
linear gradient brought the mobile phase back to 7% solution A. Finally, the column 
was re-equilibrated under isocratic conditions with 7% solution A for 10 minutes. The 
retention times for 5-methyl-THF and FA were 22 and 25 minutes, respectively, and 
the total run time was 35 minutes. Breastmilk folate concentrations were corrected for 
exogenous folate added during trienzyme digestion by subtracting blank extract LC-
MS/MS values. Intra- and inter-assay CVs were 10.0 and 12.5%, respectively for 
breastmilk 5-methyl-THF, and 5.0 and 3.5% for breastmilk FA. 
Prenatal supplement folic acid 
The FA content of the prenatal supplement was determined using the LC-
MS/MS negative ion mode method described in Nelson et al. (23). FA in the study 
prenatal supplement and NIST SRM 3280 multivitamin were extracted using the same 
protocol and quantified in the same LC-MS/MS run. The measured NIST 3280 FA 
concentration (412 mg FA / kg supplement) was consistent with the reference value 
published by Nelson et al. (413 mg/kg) (23).  
MTHFR Genotyping  
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Methylenetetrahydrofolate reductase (MTHFR) C677T genotype was 
determined after purifying the PCR products (QIAquick PCR Purification kit, Qiagen) 
(24) and sequencing the double-stranded DNA templates with an Applied Biosystems 
Automated 3730 DNA analyzer. 
Statistical Methods 
Normality was not achievable in several dependent variable baseline 
concentrations, thus Kruskal-Wallis H- and Mann-Whitney U-tests were used to test 
baseline differences in folate status marker concentrations by physiologic group. 
Kruskal-Wallis H-tests were also used to test for differences in ethnicity/race, MTHFR 
C677T genotype, choline intake randomization, and supplement use prior to study 
enrollment distribution among the physiologic groups.  
Linear mixed models (LMMs) were used to investigate folate status response 
over time when dependant variables and/or transformed dependant variables 
conformed to model assumptions. Log-transformed serum 5-methyl-THF, log-
transformed serum 5-methyl-THF + FA, square-root transformed urinary 5-methyl-
THF, square-root transformed urinary total folate, and log-transformed RBC folate 
were assessed using LMMs. Physiologic state (nonpregnant, pregnant, or lactating), 
time (study week), and choline intake level (480 or 930 mg/day) were entered as fixed 
factors and subject id was entered as random factor. Due to varying supplement use 
within and among physiologic groups before study entry, supplement use prior to 
study enrollment was entered as fixed factor. In addition, because the MTHFR C677T 
genotype can have robust effects on folate requirements (25, 26) and ethnicity may 
impact folate status (27), both were included as fixed factors in the LMMs. In the 
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initial model, all 2-way interactions between the fixed factors were included. Non-
significant interactions were progressively removed until final models were derived. 
Bonferroni corrections were made for multiple comparisons where applicable. All 
breastmilk folate variables were square-root transformed and analyzed with LMMs as 
above without the physiologic group fixed factor.  
To compare physiologic groups and assess response over time in variables that 
did not conform to LMM assumptions non-parametric analyses were used. Kruskal 
Wallis H- and Mann-Whitney U-tests were performed with baseline, week 6, and/or 
study-end concentrations as the test variable and physiologic state as the grouping 
variable. Wilcoxon rank sum tests stratified by physiologic state were utilized to 
assess change over time within and among physiologic groups. Serum FA and urinary 
FA were analyzed with non-parametric techniques. A portion of the serum FA values 
fell between the LOD and LOQ; concentrations for these samples were set equal to the 
LOQ (0.11 ng/mL) for statistical analyses.  
All statistics were performed with IBM SPSS software (version 19; SPSS Inc, 
Chicago, IL).  
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RESULTS 
Participant characteristics and baseline measurements 
Seventy-five women were included in the final analyses. Twenty-one 
nonpregnant women completed 12 weeks of the study. Twenty-three pregnant women 
completed 12 weeks of the study and 3 completed 10 weeks of the study. Twenty-five 
lactating participants completed 10 weeks of the study, 2 completed 9 weeks, and 1 
completed 8 weeks. The study-end time point was used in all statistical analyses and 
reflects the last sample collection for each study participant. The ethnicity/race of the 
study participants as well as MTHFR C677T genotype and choline supplement 
randomization were balanced among the physiologic groups (Table 1.1).  
At baseline, 85, 75, and 33% of pregnant, lactating, and nonpregnant 
participants reported consuming FA-containing supplements (P = 0.001; Table 1.1). 
The differing rates of supplement use prior to study enrollment corresponded to 
differences in baseline folate status marker concentrations with pregnant and lactating 
participants having on average higher serum folate, greater urinary folate excretion, 
and higher RBC folate than nonpregnant participants (Table 1.1).  
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TABLE 1.1 Participant characteristics and baseline folate status marker concentrations for pregnant women ~27 wk gestation, 
lactating women ~5 wk postpartum, and nonpregnant women of childbearing age
1  
 Pregnant Lactating Nonpregnant P-value 
Number of subjects 26 28 21  
Ethnicity (Caucasian /African 
American /       Hispanic / Asian / 
Other) 
16 / 1 / 4 / 4 / 1 20 / 1 / 3 / 1 / 3 14 / 2 / 2 / 1/ 2 0.804 
MTHFR genotype (CC / CT / TT) 11 / 13 / 2 11 / 15 / 2 9 / 9 / 3 0.974 
Choline intake randomization           
(480 / 930  mg/day) 
13 / 13 15 / 13 10 / 11 0.916 
% using FA-containing supplement 
prior to study enrollment
 
85
a 
75
a 
33
b 
0.001 
Serum folate (ng/mL)
2 
    
 5-methyl-THF
 
30.0 (24.4 – 34.7)a 31.4 (25.5 – 37.1)a 18.6 (14.7 – 23.7)b <0.001 
 FA
 
0.41 (0.1 –  0.65)ab 0.54 (0.42 – 0.69)b† 0.32 (0.0 – 0.45)a 0.008 
 % with detectable FA 73
ab 
93
b† 
67
a 
0.062 
 5-methyl-THF + FA
3 
30.3 (24.9 – 35.6)a 33.7 (25.5 – 40.5)a 18.7 (15.2 – 23.7)b <0.001 
 FA % of 5-methyl-THF + FA 1.5 (0.3 – 2.1) 1.9 (1.3 – 3.2) 1.5 (0.0 – 3.0) 0.222 
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Urinary folate excretion (μg / 24 hours)     
 5-methyl-THF
 
144.0 (39.7 – 411.9)a 53.5 (14.2 – 165.6)b 5.3 (3.2 – 32.5)c <0.001 
 FA
4 
5.6 (0.0 –  89.0)a 5.0 (0.0 – 18.4)a 0.0 (0.0 – 0.0)b 0.012 
 % with detectable FA 62
a 
57
a 
19
b 
0.008 
 Total folate
 
178.3 (84.0 –  475.9)a 113.4 (32.1 – 425.6)a 22.4 (10.0 – 65.8)b <0.001 
RBC folate (ng/mL)
2 
    
 Total folate
 
916.1 (735.7 – 1019.5)a 1295.8 (1095.6 – 1504.7)b 512.4 (459.5 – 572.1)c <0.001 
1
 Data were analyzed with Kruskal-Wallis tests; counts, percents, or medians (95% confidence interval) are presented; dissimilar 
superscripts within a row indicate Mann-Whitney test difference at P < 0.05 
2
 To convert ng/mL to nmol/L folate, multiply ng/mL by 2.266 
3 
 Serum 5-methyl-THF + FA was used as a proxy for serum total folate due to the lack of serum MA measurement in lactating 
group 
4
 Mean (standard deviation) urinary FA excretion (μg / 24 hours) at baseline was 62.5 (96.0) for pregnant women, 39.1 (67.8) for 
lactating women, and 11.2 (35.6) for nonpregnant women.  
†
 Difference for pregnant group vs. lactating group, P < 0.1 
Abbreviations used: 5-methyl-THF, 5-methyltetrahydrofolate; MTHFR, methylenetetrahydrofolate reductase; FA, folic acid; RBC, 
red blood cell 
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Folate dose 
Average intake of natural food folate intake was 404 µg/day (~400 DFEs) (see 
Appendix B for folate in study diet). The FA content of the prenatal multivitamin 
supplement was 750 µg FA, yielding a total folate intake of 1150 µg/day (400 µg + 
750 µg) or 1675 DFEs after adjusting for the 1.7x greater bioavailability of FA. 
Serum Folate 
Serum folate is a sensitive indicator of recent folate intake and can be a valid 
indicator of folate status (2). 5-methyl-THF is the primary form of folate found in 
circulation, while the presence and quantity of FA in fasted serum is of interest due to 
concerns regarding excess FA exposure (28).  
Serum 5-methyl-THF 
Consumption of the study folate dose (FA-containing prenatal supplement plus 
400 µg natural food folate) yielded a small but significant increase (time, P < 0.001) in 
serum 5-methyl-THF over the course of the study that did not differ among the 
physiologic groups (physiologic group x time interaction, P = 0.536) after controlling 
for ethnicity, MTHFR C677T genotype, choline intake, and supplement use prior to 
study enrollment (Figure 1.1A).  At study-end, serum 5-methyl-THF concentrations 
did not vary by physiologic group (P = 0.855; Figure 1.1A). 
Serum folic acid 
Consumption of the study folate dose did not alter serum FA concentrations 
within physiologic groups (P = 0.122–0.302) or among the cohort of participants as a 
whole (P = 0.398) over the course of the study (Figure 1.1B). At study-end, serum FA 
concentration did not vary by physiologic group (P = 0.251; Figure 1.1B). 
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Unmetabolized FA was present in fasted serum among 81%, 89%, and 81% of 
pregnant, lactating, and nonpregnant women, respectively, at study-end.  
The percent of serum FA relative to serum 5-methyl-THF + FA, i.e. serum 
total folate, was small and did not vary over the course of the study within physiologic 
groups (P = 0.163–0.376). However, among the cohort of participants as a whole, FA 
percent of serum 5-methyl-THF + FA tended to decrease (P = 0.058) over the course 
of the study from 1.6% at baseline to 1.2% at study-end; FA percent of serum 5-
methyl-THF + FA did not vary by physiologic group (P = 0.614) at study-end.  
Serum 5-methyl-THF + folic acid 
Similar to serum 5-methyl-THF, consumption of the study folate dose 
increased (time, P < 0.001) serum 5-methyl-THF + FA, i.e. total folate, over the 
course of the study that did not differ among the physiologic groups (physiologic 
group x time interaction, P = 0.275) after controlling for ethnicity, MTHFR C677T 
genotype, choline intake, and supplement use prior to study enrollment (Figure 1.1C).  
At study-end, serum 5-methyl-THF + FA concentrations did not vary by physiologic 
group (P = 0.893; Figure 1.1C). The study folate intake yielded study-end serum 5-
methyl-THF + FA (i.e., total folate) concentration estimates exceeding 20 ng/mL 
(Figure 1.1C), an indicator of “high” folate status (5).   
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Figure 1.1 legend 
Serum concentrations of 5-methyl-THF (A); FA (B); and 5-methyl-THF + FA (C) 
among third-trimester pregnant women (n = 26), lactating women 5–15 weeks 
postpartum (n = 28), and nonpregnant women of childbearing age (n = 21) consuming 
a FA-containing prenatal supplement plus 400 µg natural food folate for 10–12 weeks. 
Statistical analyses for 5-methyl-THF and 5-methyl-THF + FA were performed with 
linear mixed models. Statistical analyses for FA were performed with Kruskal-Wallis 
and Mann-Whitney tests. All participants were included in the analyses. Plotted data 
for 5-methyl-THF and 5-methyl-THF + FA are back transformed predicted means and 
95% confidence intervals derived from linear mixed models; medians with 95% 
confidence intervals were plotted for FA. Study-end was week 10 for lactating 
participants and week 12 for pregnant and nonpregnant participants. Serum folate 
concentrations did not differ (P = 0.251–0.876) among physiologic groups at study-
end. *indicates serum folate concentrations increased (P < 0.001) from baseline to 
study-end. Physiologic state did not interact with time for serum 5-methyl-THF and 5-
methyl-THF + FA concentrations (P = 0.251–0.893); distribution of the serum FA 
data did not allow this interaction to be tested. To convert ng/mL to nmol/L folate, 
multiply ng/mL by 2.266. Abbreviations: 5-methyl-THF, 5-methyltetrahydrofolate; 
FA, folic acid 
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Urinary Folate 
Twenty-four hour urinary folate excretion is a useful folate status indicator 
because it reflects saturable intracellular retention and renal reabsorption mechanisms 
related to folate utilization and requirement (29). Further, in contrast to fasting serum 
folate which reflects folate status at its lowest point, 24-hour urinary folate excretion 
encompasses the rise and fall of circulating folate and is an indicator of “average” 
folate status throughout the 24-hour interval (30). Urinary folate species of primary 
interest in the era of FA fortification (and/or among those using FA-containing 
supplements) are 5-methyl-THF, the main form in circulation, and FA.  
Urinary 5-methyl-THF 
Consumption of the study folate dose yielded urinary 5-methyl-THF that 
differed among physiologic groups (physiologic group x time, P < 0.001) after 
controlling for ethnicity, MTHFR C677T genotype, choline intake, and supplement 
use prior to study enrollment. Among lactating and nonpregnant women, urinary 5-
methyl-THF excretion increased (both, P ≤ 0.001) over the course of the study 
(Figure 1.2A).  However, among pregnant women, urinary 5-methyl-THF did not 
change (P = 1.0) over the course of the study (Figure 1.2A).  At study-end, pregnant 
women were excreting less 5-methyl-THF than lactating (P = 0.006) and nonpregnant 
(P < 0.001) women, which did not differ (P = 0.251) from each other (Figure 1.2A). 
Urinary folic acid 
Consumption of the study folate dose increased (P < 0.001) urinary FA 
excretion among nonpregnant women over the course of the study; however, FA 
excretion among pregnant and lactating women did not change (P = 0.162–0.976) over 
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the course of the study (Figure 1.2B). At study-end, pregnant and lactating women, 
which did not differ (P = 0.941) from each other, excreted less (both P < 0.001) 
urinary FA than nonpregnant women (Figure 1.2B). Unmetabolized FA was present in 
77%, 89%, and 100% of 24-hour urine collections among pregnant, lactating, and 
nonpregnant women, respectively, at study-end. 
Urinary total folate 
Similar to urinary 5-methyl-THF, consumption of the study folate dose yielded 
urinary total folate excretion that differed among physiologic groups (physiologic 
group x time, P < 0.001) after controlling for ethnicity, MTHFR C677T genotype, 
choline intake, and supplement use prior to study enrollment. Among nonpregnant 
women, urinary total folate increased (P < 0.001) over the course of the study, and 
among lactating women, urinary total folate tended to increase (P = 0.093) over the 
course of the study (Figure 1.2C). However, among pregnant women, urinary total 
folate did not change (P = 1.0) over the course of the study (Figure 1.2C).   
At study-end, pregnant and lactating women excreted significantly less (both P 
≤ 0.004) total folate than nonpregnant women, and pregnant women tended to excrete 
less (P = 0.075) total folate than lactating women (Figure 1.2C).The study folate 
intake yielded substantial amounts of urinary folate at study-end, with mean urinary 
total folate excretion equivalent to approximately 9%, 20%, and 43% of daily total 
folate intake (1150 µg) for pregnant, lactating, and nonpregnant women, respectively.  
Analyses with values adjusted with urinary creatinine excretion (31) to correct 
for possible incomplete 24-hour urine collection produced the same results for all 
urinary folate variables (data not shown).  
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Figure 1.2 legend 
Urinary excretion of 5-methyl-THF (A); FA (B); and total folate (C) among third-
trimester pregnant women (n = 26), lactating women 5–15 weeks postpartum (n = 28), 
and nonpregnant women of childbearing age (n = 21) consuming a FA-containing 
prenatal supplement plus 400 µg natural food folate for 10–12 weeks. Statistical 
analyses for 5-methyl-THF and total folate were performed with linear mixed models. 
Statistical analyses for FA were performed with Kruskal-Wallis and Mann-Whitney 
tests. All participants were included in the analyses. Plotted data for 5-methyl-THF 
and total folate excretion are back transformed predicted means and 95% confidence 
intervals derived from linear mixed models; medians with 95% confidence intervals 
were plotted for FA excretion. Study-end was week 10 for lactating participants, and 
week 12 for pregnant and nonpregnant participants. The interaction of physiologic 
state and time was significant (P < 0.001) for urinary 5-methyl-THF and total folate 
excretion; distribution of the urinary FA data did not allow for this interaction to be 
tested. Dissimilar letters indicate differences (P < 0.01) between physiologic groups at 
study-end. 
†
indicates pregnant group and lactating group tended to be different (P < 
0.1) at study-end.  *indicates urinary folate concentrations increased (P < 0.01) from 
baseline to study-end within designated physiologic groups. § indicates folate 
excretion tended to increase (P < 0.1) from baseline to study-end within lactating 
group. To convert ng/mL to nmol/L folate, multiply ng/mL by 2.266. Abbreviations: 
5-methyl-THF, 5-methyltetrahydrofolate; FA, folic acid 
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RBC Folate 
RBC folate is an indicator of long-term folate status and is less sensitive to 
acute changes in folate intake (2).  
Consumption of the study folate dose yielded RBC folate concentrations that 
differed among physiologic groups (physiologic group x time, P = 0.002) after 
controlling for ethnicity, MTHFR C677T genotype, choline intake, and supplement use 
prior to study enrollment. Among pregnant women and nonpregnant women, RBC 
folate concentrations increased (P = 0.019 and 0.044, respectively) slightly (~10%) 
over the course of the study, while among lactating women, RBC folate did not 
change (P = 0.107) over the course of the study (Figure 1.3).  
At study-end, lactating women had higher (P ≤ 0.002) RBC folate than both 
pregnant and nonpregnant women, and pregnant women had higher (P < 0.001) RBC 
folate than nonpregnant women (Figure 1.3). RBC folate concentrations are related to 
the 120 day lifespan of erythrocytes and may take up to 40 weeks to achieve steady 
state (32). Thus it is likely study participants had not fully acclimated to the study 
folate dose by study-end, and differences by physiologic group are not necessarily 
reflective of differences in physiologic utilization and/or requirement.  
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Figure 1.3 legend 
RBC folate concentrations among third-trimester pregnant women (n = 26), lactating 
women 5–15 weeks postpartum (n = 28), and nonpregnant women of childbearing age 
(n = 21) consuming a FA-containing prenatal supplement plus 400 µg natural food 
folate for 10–12 weeks. Statistical analyses were performed with and reported from a 
linear mixed model. All participants were included in the analyses. Plotted data are 
back transformed predicted means and 95% confidence intervals derived from linear 
mixed models. Study-end was week 10 for lactating participants, and week 12 for 
pregnant and nonpregnant participants. The interaction of physiologic state and time 
was significant (P = 0.002). Dissimilar letters indicate differences (P < 0.01) between 
physiologic groups at study-end.  *indicates RBC folate increased (P < 0.05) from 
baseline to study-end within designated physiologic groups. To convert ng/mL to 
nmol/L folate, multiply ng/mL by 2.266. Abbreviations: 5-methyl-THF, 5-
methyltetrahydrofolate; FA, folic acid; RBC, red blood cell 
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Breastmilk folate 
Breastmilk folate represents a route of folate loss among lactating women and 
is the primary source of folate for exclusively breastfed infants (2).  
Consumption of the study folate dose did not alter breastmilk 5-methyl-THF 
(P = 0.232) or breastmilk total folate (P = 0.244) concentrations over the course of the 
study after controlling for ethnicity, MTHFR C677T genotype, choline intake, and 
supplement use prior to study enrollment (Figure 1.4A; Table 1.2). However, 
consumption of the study folate dose resulted in greater (time, P < 0.001) breastmilk 
FA concentrations over the course of the study (Figure 1.4A; Table 2). Moreover, 
supplement use prior to study enrollment interacted (P < 0.001) with study week 
(time) to affect breastmilk FA concentrations.   
The relationship among supplement use prior to study enrollment, time and 
breastmilk FA concentrations was further explored because prior research has not 
shown a relationship between maternal folate (or FA) intake and breastmilk folate 
concentrations (33,34). Interestingly, breastmilk FA concentrations increased (P = 
0.001) from baseline to study-end only among women not taking a supplement prior to 
study enrollment; there was no change (P = 1.0) in breastmilk FA concentrations 
among women taking a FA-containing supplement at baseline (Figure 1.4B; Table 
1.2). At baseline, breastmilk FA concentrations were lower (P < 0.001) among women 
not consuming a supplement prior to study enrollment; however, at week 6 (P = 
0.324) and study-end (P = 0.796), there were no differences in breastmilk FA 
concentrations based on supplement use prior to study enrollment (Figure 1.4B; Table 
1.2). In addition, the ratio of breastmilk FA : breastmilk total folate was significantly 
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lower (P < 0.001) among lactating women not using a supplement prior to study 
enrollment at baseline; however, at week 6 (P = 0.242) and at study-end (P = 0.174) 
there were no differences in the breastmilk FA : breastmilk total folate ratio based on 
supplement use prior to study enrollment (Table 1.2). The ratio of breastmilk 5-
methyl-THF : breastmilk total folate did not change (P = 0.889) over the course of the 
study.   
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TABLE 1.2 Breastmilk folate concentrations for lactating women 5–15 weeks postpartum (n = 28) at baseline and following the 
consumption of a FA-containing prenatal supplement plus 400 µg naturally occurring food folate for 10 weeks
1 2 
 Baseline Study-end P-value 
5-methyl-THF (ng/mL)
 
14.0 (10.8 – 17.6) 16.3 (12.8 – 20.2) 0.232 
Total folate (ng/mL) 56.2 (48.8 – 64.2) 61.8 (54.1 – 70.0) 0.244 
FA (ng/mL)    
 All participants
 
16.2 (11.8 – 21.3) 24.1 (18.7 – 30.3) < 0.001 
 No supplement prior, n = 7 8.4 (3.5 – 15.4)a  21.4 (12.9 – 31.9) < 0.001 
 Supplement prior, n = 21
  
26.6 (20.9 – 33.1)b 27.1 (21.3 – 33.6) 0.984 
FA : total folate    
 All participants
 
0.32 (0.26 – 0.39) 0.40 (0.34 – 0.46) 0.041 
 No supplement prior 0.18 (0.07 – 0.30)a  0.36 (0.25 – 0.46) 0.007 
 Supplement prior 0.46 (0.40 – 0.52)b 0.44 (0.38 – 0.50) 0.814 
1 
 Data were analyzed with linear mixed models; back transformed predicted means (95% confidence interval) are presented;  P - 
value refers to baseline vs. study-end Bonferroni corrected pairwise comparison derived from linear mixed model; dissimilar 
superscripts within a column indicate baseline differences (Bonferroni corrected pairwise comparison at P < 0.001)  between groups 
derived from linear mixed model.  
2
  To convert ng/mL to nmol/L folate, multiply ng/mL by 2.266 
Abbreviations used: 5-methyl-THF, 5-methyltetrahydrofolate; FA, folic acid 
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Figure 1.4 legend 
Breastmilk 5-methyl-THF, total folate, and FA concentrations among lactating women 
(n = 28) consuming a FA-containing prenatal supplement plus 400 µg natural food 
folate for 10 weeks (A). Breastmilk FA concentrations comparing study participants 
that were consuming a FA-containing supplement prior to study enrollment (n = 21) to 
study participants that were not consuming a FA-containing supplement prior to study 
enrollment (n = 7) (B). Statistical analyses were performed with linear mixed models. 
All participants were included in the analyses. Plotted data are back transformed 
predicted means and 95% confidence intervals derived from linear mixed models. The 
interaction of breastmilk folic acid and supplement use prior to study enrollment was 
significant (P < 0.001). Dissimilar letters indicate differences (P < 0.001) between 
groups at designated time point.*indicates designated breastmilk folate increased (P < 
0.01) from baseline to study-end. To convert ng/mL to nmol/L folate, multiply ng/mL 
by 2.266. Abbreviations: 5-methyl-THF, 5-methyltetrahydrofolate; FA, folic acid. 
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DISCUSSION 
This is the first controlled feeding study to comprehensively assess and 
compare folate status response to a known dose (FA-containing prenatal supplement 
plus 400 µg natural food folate) among third-trimester pregnant women, lactating 
women 5–15 weeks postpartum, and nonpregnant women of childbearing age. Three 
main findings emerged: (i) the study dose yielded supranutritional folate status in all 
women regardless of physiologic state; (ii) folate utilization is greater during the third-
trimester of pregnancy than during lactation 5–15 weeks postpartum; and (iii) 
breastmilk folate species are responsive to maternal folate intake.  
Consumption of the study folate dose yielded supranutritional folate status 
Supranutritional folate status is indicated by folate status marker 
concentrations that (i) far surpass adequacy cut-offs and (ii) suggest metabolic 
capacity has been exceeded. Such status is achieved with folate intakes that are above 
what is reachable through consumption of natural food folate. Several biomarkers 
examined in the present study demonstrate that consumption of 400 µg natural food 
folate plus a FA-containing prenatal supplement yielded supranutritional status. First, 
study-end serum folate concentration estimates far exceeded 20 ng/mL, which is 
considered a marker of “high” folate status because it corresponds to the 95th 
percentile of population-wide folate status pre-FA fortification (5). Second, at study-
end, 84% of women had detectable unmetabolized FA in fasted serum, and 100, 77, 
and 89% of nonpregnant, pregnant, and lactating women, respectively, excreted 
unmetabolized FA in their urine. Third, total urinary folate excretion represented ~9–
43% of total folate intake, i.e. ~100–500 µg/day.  
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The impact of supranutritional folate status on health is unclear; however, most 
concerns regard masking of vitamin B12 deficiency, folate/ B12 imbalance, putative 
roles in cancer promotion, and exposure to unmetabolized FA (28). Many over-the-
counter prenatal supplements contain 800–1000 µg FA (1360–1700 DFEs) (9), an 
amount that exceeds all recommended intakes for women of childbearing age and 
approaches/meets the 1000 µg tolerable upper level of intake (2). Given underlying 
folate sufficiency (5), current folate/FA intakes (35), and evidence of supranutritional 
folate status in the present study, reduction of prenatal supplement FA doses seems 
prudent.  
Although conducted under controlled conditions, the results of this study are 
broadly generalizable in FA-fortified populations because study participants consumed 
an over-the-counter prenatal supplement and natural folate from a mixed diet. 
However, it should be noted that the supranutritional folate status achieved with this 
study’s folate dose should not be extrapolated to less folate-replete populations.  
Response by physiologic state 
In the present study, intact 24-hour urinary folate excretion, which represents 
“average” folate status across the collection period, proved the most informative folate 
status marker (vs. fasted serum and RBC folate concentrations) in comparing folate 
utilization and requirement by physiologic group. Third-trimester pregnant women 
demonstrated the greatest folate utilization by excreting less urinary 5-methyl-THF 
and less total folate than lactating and nonpregnant women at study-end. Meanwhile, 
lactating women demonstrated greater folate utilization than nonpregnant women by 
excreting less urinary total folate and FA at study-end. The dose in the present study 
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far exceeded the current RDAs for pregnant and lactating women, thus in order to 
further refine RDA recommended intakes, dose response studies with intake levels 
approximating current RDAs and/or EARs are necessary.  
Breastmilk folate 
Results of the present study confirm other findings (33,34) that breastmilk total 
folate concentrations are maintained at constant levels regardless of maternal folate 
intake, i.e., breastmilk total folate concentrations did not vary based on supplement 
use prior to study enrollment nor were changes observed over the course of the study. 
However, results of the present study indicate, for the first time, that the distribution of 
folate species in breastmilk is related to maternal folate intake.  
Previously published studies have reported 5-methyl-THF and FA make up 
20–60% (36,37) and  8–40% (34,37) of breastmilk total folate, respectively, indicating 
a broad distribution of breastmilk folate species. A significant proportion of breastmilk 
folate is bound to the protein folate receptor  (FR) (36,38). The amount of FR in 
breastmilk is positively correlated (r = 0.71, P < 0.001) (38) with breastmilk total 
folate concentrations and FR may play a role in regulating breastmilk folate 
concentrations (34,38). Among folate forms, FR has the highest affinity for FA (39). 
In the present study, the study FA dose increased breastmilk FA, without altering 
breastmilk total folate concentrations, among lactating women who did not consume a 
FA-supplement prior to study-enrollment. The maintenance of breastmilk total folate 
concentrations in the midst of rising breastmilk FA concentrations implies that FA is 
displacing reduced folate forms from FR in breastmilk.  The high percentage of 
breastmilk FA (~40%) arising from the study FA dose may be of concern as 
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bioavailability studies with milk suggest that absorption of FA is less than 5-methyl-
THF when bound to FR (40).   
Conclusions 
Supranutritional folate status resulted from the consumption of a FA-
containing prenatal supplement plus 400 µg natural food folate. At study-end, serum 
folate concentrations did not vary by physiologic group with the increased folate 
requirements of pregnant and lactating women only apparent via differences in urinary 
folate excretion. Breastmilk total folate concentrations did not change in response to 
the study folate dose; however, the proportion of FA in breastmilk increased. Given 
unresolved concerns about exposure to excess FA (for women of childbearing age as 
well as breastfeeding infants) and the widespread folate adequacy of our post-FA 
fortification population, it appears prudent to reduce the amount of FA in prenatal 
supplements to levels more in line with DRI recommended intakes. 
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CHAPTER 2 
Choline intake and pregnancy influence phosphatidylcholine docosahexaenoic acid 
enrichment among third trimester pregnant and nonpregnant women 
 
ABSTRACT 
Background: Phosphatidylcholine (PC) produced via the S-adenosylmethionine 
(SAM) dependant phosphatidylethanolamine (PE) N-methyltransferase (PEMT) 
pathway is enriched with docosahexaenoic acid (DHA). DHA plays a critical role in 
fetal development and is linked to cardiovascular and mental health endpoints in 
adults. It is unknown whether choline, which can serve as a source of SAM methyl 
donors, influences PC-DHA enrichment among pregnant and nonpregnant women.  
Objective: This study tested whether choline intake impacted parameters of choline 
related lipid metabolism, i.e. erythrocyte and plasma PC-DHA and PC:PE ratio, 
among third-trimester pregnant and nonpregnant women.  
Design: Pregnant (n =26) and nonpregnant (n =21) women consumed 430 or 930 mg 
choline/d and a daily DHA supplement under controlled intake conditions for 12 wks. 
Blood was collected at baseline, study-midpoint, and study-end. 
Results: Pregnant women had greater (P= 0.01–0.001) PC-DHA than nonpregnant 
women at baseline. Erythrocyte and plasma PC-DHA increased (P < 0.001) among 
pregnant and nonpregnant women regardless of choline intake. However, among 
nonpregnant women consumption of 930 mg choline/d led to greater (P= 0.011) 
erythrocyte PC-DHA and a more rapid increase (P< 0.001) of plasma PC-DHA. 
  
47 
Lower (P= 0.001–0.015) erythrocyte and plasma PC:PE among pregnant women 
throughout the study was not modified by choline intake.  
Conclusions: A higher choline intake may facilitate flux through the PEMT pathway 
resulting in greater PC-DHA concentrations and increased delivery of DHA to 
peripheral tissues among nonpregnant women. The increased production of PC-DHA 
during pregnancy is indicative of elevated PEMT activity and a higher demand for 
methyl donors. This trial was registered at clinicaltrials.gov as NCT01127022.  
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INTRODUCTION 
The ubiquitous phospholipid phosphatidylcholine (PC) consists of 2 fatty acid 
constituents linked to a glycerophosphocholine backbone. The fatty acid composition 
of the PC molecule is a function of the pathway by which it is synthesized. PC 
produced via the phosphatidylethanolamine N-methyltransferase (PEMT) pathway is 
enriched in docosahexaenoic acid (DHA) (1) . In contrast, PC generated by the CDP-
choline pathway is enriched in linoleic acid and oleic acid (1).  
Adequate DHA nutrition is essential for health throughout the lifespan. The 
fetus requires DHA for proper development of the brain and immune systems (2,3). In 
adults, DHA nutrition is linked to inflammation, brain function, reproductive health, 
and cardiovascular disease (4). Following incorporation into VLDL, PC-DHA 
produced via PEMT is available for the fetus in pregnant women and transported to 
peripheral tissues in both pregnant and nonpregnant women. Thus, PEMT plays an 
essential role in mobilization and export of DHA from liver (5).  
PEMT substrate concentrations including methyl donors (e.g. folate and the 
choline metabolite betaine) and supplementary DHA may influence PEMT activity 
and impact PC fatty acid composition in plasma and erythrocytes (6). However, the 
impact of a higher choline intake on PC-DHA enrichment in plasma and erythrocytes 
among pregnant and nonpregnant women is unknown. Erythrocyte PC-DHA 
enrichment is of particular interest as it is a more stable marker of status and is 
correlated with that of hepatic PC (7). In addition, erythrocyte DHA accretion 
correlates with brain, retina, and adipose DHA accretion (8).  
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The ratio of PC to PE in cellular membranes is tightly regulated (9,10). 
Changes in the PC:PE ratio can impair membrane functionality and a reduced 
membrane PC has been found during choline deficiency and in patients with non-
alcoholic fatty liver disease (NAFLD), a condition associated with deranged choline 
metabolism (11,12). It is unknown whether choline intake impacts the PC:PE ratio in 
healthy pregnant and nonpregnant women, or whether the increased requirement for 
choline during pregnancy alters the PC:PE ratio in erythrocytes and/or plasma. 
The primary aim of this study was to test whether choline intake under 
controlled conditions impacted erythrocyte and plasma PC fatty acid constituents and 
the PC:PE ratio among third-trimester pregnant and nonpregnant women. Because 
PEMT activity is upregulated by estrogen (13), which rises during pregnancy, a 
secondary aim was to investigate the impact of pregnancy on erythrocyte and plasma 
PC fatty acid constituents and PC:PE.   
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STUDY PARTICIPANTS AND METHODS 
Study Participants 
Nonpregnant and third trimester pregnant (27 weeks gestation) women aged ≥ 
21 y were recruited from the Ithaca, NY area from January 2009–October 2010 as 
described by Yan et al. (14). During the screening phase, interested individuals 
provided a blood sample for blood chemistry profiling and complete blood count 
analyses, and completed a health history and demographics questionnaire (see 
Appendix B for questionnaires). Important inclusion criteria were: (i) general 
healthiness as determined by the questionnaire, blood chemistry profile, and complete 
blood count; (ii) no drug or alcohol use; (iii) normal kidney and liver function; and (iv) 
willingness to comply with study protocol, including agreement to eat ≥ 5 meals at the 
on-site location and not consume food or beverages outside what was provided by the 
study. Additional inclusion criteria for pregnant women were singleton pregnancy and 
no pregnancy associated complications, e.g., preeclampsia, gestational diabetes. 
Exclusion criteria included: inability to comply with study protocols and use of 
prescription medications known to affect liver function. Eligible pregnant women 
were admitted to the study on a rolling basis at 26–29 weeks gestation and eligible 
nonpregnant women were added as scheduling and space constraints allowed until the 
desired number of participants completed the study (14). 
The study protocol was reviewed and approved by the Institutional Review 
Board for Human Study Participant Use at Cornell University and at the Cayuga 
Medical Center (the hospital where pregnant participants delivered their babies; 
Ithaca, NY). Study participants were compensated for participation and informed 
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consent was obtained from all participants prior to their entry into the study (see 
Appendix B for informed consent documents).  
Study Design, Diet, and Supplements 
Design 
This study was part of a controlled feeding study conducted in nonpregnant and 
pregnant women randomized to consume 480 or 930 mg choline/d for 12 weeks (14) 
through a combination of dietary choline (~380 mg/day) and supplemental choline 
chloride (100 or 550 mg/day). Throughout the controlled feeding period all 
participants also consumed a daily 200 mg DHA supplement in order to achieve the 
recommended intake of this nutrient for pregnant women (15). Blood was collected 
and processed as previously described (14) at baseline and study weeks 6, 10, and 12.  
Diet 
The study diet provided ~380 mg choline/d (14). Lipid soluble forms of choline 
including PC, sphingomyelin, and lysophosphatidylcholine, contributed 236 mg 
choline/day, and water-soluble forms including free choline, phosphocholine, and 
glycerophosphocholine contributed 142 mg choline/d (14) (see Appendix B for study 
diet). In addition, the diet provided 100 mg betaine/day. The study diet supplied ~2000 
kcal/d which could be modified to meet caloric requirements by the addition or 
subtraction of non-nutritive food items (14). Food was prepared in the Francis A. 
Johnston and Charlotte M. Young Human Metabolic Research Unit (HMRU) at 
Cornell University. Study participants consumed ≥ 5 meals/ week under the 
supervision of study personnel at the HMRU; all other food and beverages were 
provided as take-aways.  
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Supplements 
Choline supplements were prepared by study personnel as described by Yan et 
al. (14). Briefly, pharmaceutical grade choline chloride (Balchem) was dissolved in 
autoclaved drinking water and amounts containing 100 mg and 550 mg choline were 
dispensed into sterile 50 mL conical tubes containing cranberry-grape juice and stored 
at -20
o
C in HMRU freezers; 1-2 days prior to consumption, supplements were thawed 
at 4
o
C 
In addition, study participants consumed a daily 200 mg DHA supplement 
(Neuromins, Nature’s Way Products, Springville, Utah), a daily over-the-counter 
prenatal multivitamin supplement (Pregnancy Plus®, Fairhaven Health, LLC, 
Bellingham, WA), and a thrice weekly potassium/magnesium supplement (General 
Nutrition Corp., Pittsburgh, PA) in order to achieve recommended nutrient intake 
levels not met with the study diet (15,16). When eating on-site, participants consumed 
supplements under the supervision of study personnel. Otherwise, supplements were 
provided in baggies along with take-away meals and participants were instructed to 
consume the supplements with a meal of their choice.   
Compliance 
The study protocol was well-tolerated with 92% of enrolled participants 
completing the study (21 of 22 nonpregnant and 26 of 29 pregnant). Reasons for 
stopping the study included nausea, early delivery, personal challenges, and food 
dislikes (14).  
Study participants completed daily checklists indicating they received and 
consumed all menu items and supplements. For meals consumed off-site, participants 
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were asked to return all empty conical tubes, baggies, and take-away food containers 
to study personnel during their next visit to the HMRU. In addition, study personnel 
had daily contact with participants throughout the study to maintain positive rapport 
and enhance compliance. 
Sample Collection and Processing 
Fasting venous blood was drawn at baseline and study weeks 6, 10, and 12 in 
the HMRU ward by a trained phlebotomist. Blood samples were collected in EDTA 
and serum separator tubes, processed within 2 hours, and stored in cryostat tubes at -
80 
o
C until analysis as previously described (14).  
Analytic Measurements 
Erythrocyte and plasma PC fatty acid constituents  
Erythrocyte and plasma PC fatty acids constituents were quantified via gas 
chromatography-mass spectrometry (15). Fatty acid constituent data is presented as % 
total PC fatty acids. 
Erythrocyte and plasma phospholipids 
PC and PE were quantified from washed, packed red blood cells and plasma 
with a high performance liquid chromatography-evaporative light scattering detection 
method (17).  
Genotyping  
Select genetic variants impacting  choline metabolism 
(methylenetetrahydrofolate reductase (MTHFR) C677T (18); 
methylenetetrahydrofolate dehydrogenase (MTHFD1) G11958A (19); and betaine-
homocysteine S-methyltransferase (BHMT) G724A (20) were determined by 
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sequencing the double-stranded DNA templates with an Applied Biosystems 
Automated 3730 DNA analyzer. 
Statistical Methods 
The impact of choline intake and physiologic state on PC-DHA (22:6n-3) and 
PC-arachidonic acid (ARA, 20:4n-6) where examined separately. Additional 
dependant variables included: the sum of PC- eicosapentaenoic acid (EPA, 20:5n-3), 
PC-omega-3 docosapentaenoic acid (DPAn3, 22:5n-3), PC-omega-6 docosapentaenoic 
acid (DPAn6, 22:5n-6), and PC-docosatetraenoic acid (DTA, 22:4n-6); and an index 
of the main unsaturated species generated through the CDP-choline pathway, PC-
linoleic acid (18:2n-6) and PC-oleic acid (18:1n-9). 
Mann-Whitney U-tests were used to test baseline differences in participant 
characteristics and dependent variable values between physiologic groups and baseline 
differences by choline intake level within physiologic groups.   
Linear mixed models (LMMs) were used to determine the impact of choline 
intake on dependant variables after grouping by physiologic state. In this set of 
LMMs, time (study week), choline intake (480 or 930 mg/day), and their interactions 
were entered as fixed factors; subject identifier was entered as random factor; the 
baseline dependant variable value was entered as covariate; and the interaction 
between baseline value and time was included. Plasma EPA+DPAs+DTA, plasma 
PC:PE, and erythrocyte PC:PE underwent natural log transformation prior to analysis 
with LMMs; all other dependent variables did not require transformation to satisfy 
model assumptions.   
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A second set of LMMs were used to illustrate the impact of physiologic state, 
i.e. pregnancy, on dependant variables over the course of the study. Physiologic state 
(nonpregnant or pregnant), time (study week), and their interactions were entered as 
fixed factors; subject identifier was entered as random factor; and choline intake (480 
or 930 mg/day) was controlled for.  
Additional covariates/factors considered in initial models included: age, 
ethnicity, BMI, serum folate concentrations, and the MTHFR C677T, MTHFD1 
G11958A, and/or BHMT G724A genotypes. Non-significant interactions were 
progressively removed until final models were derived. Bonferroni corrections were 
made for multiple comparisons where applicable.  
All statistics were performed with IBM SPSS software (version 19; SPSS Inc, 
Chicago, IL).
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RESULTS 
Participant characteristics and baseline values 
Forty-seven women were included in the final analyses. Twenty-one 
nonpregnant and 23 pregnant women completed 12 weeks of the study and 3 pregnant 
women completed 10 weeks of the study. The study-end time point was used in all 
statistical analyses and reflects the last sample collection for each study participant. 
The ethnicity/race of the study participants as well as MTHFR C677T, MTHFD1 
G11958A, and BHMT G724A genotypes were balanced by physiologic state and 
choline intake group (Table 2.1).  
In erythrocytes at baseline, pregnant women had greater (P = 0.001) PC-DHA 
enrichment and lower (P = 0.001) PC-ARA enrichment than nonpregnant women; 
enrichment of other erythrocyte PC-fatty acid parameters did not differ (P = 0.487–
0.674) (Table 2.1). In plasma, pregnant women had greater PC-DHA (P = 0.010) and 
PC-linoleic+oleic (P = 0.047), and lower PC-ARA (P < 0.001) and PC-
EPA+DPAs+DTA (P = 0.028) enrichment than nonpregnant women (Table 2.1). 
Pregnant women had lower erythrocyte (P < 0.001) and plasma (P = 0.014) PC:PE 
than nonpregnant women at baseline (Table 2.1). Plasma PC-EPA+DPAs+DTA was 
lower (P = 0.014) among pregnant women randomized to the 930 mg choline/d group; 
no other dependant variables varied by choline intake at baseline (Table 2.1).  
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TABLE 2.1 Participant characteristics and baseline lipid values for pregnant women ~27 wk gestation and nonpregnant women of 
reproductive age randomized to consume 480 or 930 mg choline/day
12 
 Pregnant Nonpregnant 
 480 mg/d 930 mg/d All 480 mg/d 930 mg/d All 
Number of subjects
2 
13 13 26 10 11 21 
Ethnicity (Caucasian /African 
American / Hispanic / 
Asian / Other)
2 
9/0/2/1/1 7/1/2/3/0 16/1/4/4/1 8/1/1/0/0 6/1/1/1/2 14/2/2/1/2 
MTHFR genotype (CC / CT / 
TT)
2 
5/8/0 6/5/2 11/13/2 3/4/3 6/5/0 9/9/3 
MTHFD1 genotype (GG / GA / 
AA)
2 
6/6/1 4/5/4 10/11/5 1/7/2 2/8/1 3/15/3 
BHMT  genotype (GG / GA / 
AA / undeterminable)
2 
8/3/1/1 7/2/1/3 15/5/2/4 4/6/0/0 9/1/1/0 13/7/1/0 
Erythrocyte PC fatty acids (% of total)
3
     
 
 DHA 3.1 ± 0.5 2.8 ± 0.8 2.9 ± 0.6 2.4 ± 0.8 2.1 ± 0.4 2.3 ± 0.6
a 
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 ARA 7.2 ± 1.4 7.6 ± 1.7 7.4 ± 1.6 8.6 ± 1.2 9.1 ± 1.5 8.9 ± 1.4
a 
 EPA + DPAs + DTA 1.8 ± 0.4 1.9 ± 0.3 1.9 ± 0.3 1.7 ± 0.4 1.9 ± 0.4 1.8 ± 0.4 
 Linoleic + Oleic 35.6 ± 2.2 35.5 ± 2.2 35.6 ± 2.1 35.3 ± 2.1 37.0 ± 2.6 36.2 ± 2.5 
Plasma PC fatty acids (% of total)
3
      
 DHA 4.4 ± 0.8 3.8 ± 1.0 4.1 ± 0.9 3.6 ± 1.2 2.9 ± 0.4 3.2 ± 0.9
b 
 ARA 12.4 ± 2.3 12.1 ± 2.3 12.2 ± 2.3 15.7 ± 1.7 16.5 ± 2.6 16.1 ± 2.2
a 
 EPA + DPAs + DTA 2.3 ± 0.3 2.0 ± 0.2* 2.2 ± 0.3 2.4 ± 0.6 2.5 ± 0.6 2.4 ± 0.5
c 
 Linoleic + Oleic 33.2 ± 2.4 33.6 ± 2.7 33.4 ± 2.5 31.9 ± 3.2 32.2 ± 3.2 32.0 ± 3.1
c 
Erythrocyte PC:PE
4 
1.0 (0.9–1.1) 1.0 (0.9–1.0) 1.0 (0.9–1.0) 1.2 (1.0–1.5) 1.2 (1.0–1.3) 1.2 (1.1–1.3)a 
Plasma PC:PE
4 
40.4 (30.1–
51.0) 
41.6 (30.3–
53.3) 
40.6 (34.1–
46.5) 
63.6 (17.6–
86.0) 
59.8 (20.2–
93.6) 
62.1 (48.8–
75.3)
c 
1
 Data were analyzed with Mann-Whitney U-tests.  
abc 
All pregnant compared with all nonpregnant: 
a
 P ≤ 0.001, b P ≤ 0.01, c P ≤ 0.05.  
* Indicates difference within physiologic group between choline intake levels, P < 0.05. 
2
 counts, 
3
 means ± st dev presented, or 
4
 medians (95% confidence interval) 
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Impact of Choline Intake on Erythrocyte and Plasma PC-fatty acids and PC:PE ratio 
Third-trimester pregnant women 
Erythrocytes: After controlling for baseline values and covariates, choline 
intake did not impact (P = 0.543) erythrocyte PC-DHA in pregnant women. However, 
choline intake and time tended to interact (P = 0.066) to influence erythrocyte PC-
ARA (Figure 2.1). Erythrocyte PC-ARA enrichment did not differ by choline intake 
at week 6 (P = 0.942) or study-end (P = 0.162); however, PC-ARA decreased (P = 
0.02) from week 6 to study-end only among women consuming 930 mg choline/d (430 
mg choline/d group, P = 0.286). Choline intake did not impact erythrocyte PC-
EPA+DPAs+DTA (P = 0.827) or PC-linoleic+oleic (P = 0.246) among pregnant 
women.  
Plasma: After controlling for baseline values and covariates, choline intake did 
not impact plasma PC-DHA (P = 0.480), PC-ARA (P = 0.990), PC-EPA+DPAs+DTA 
(P = 0.681), or PC-linoleic+oleic (P = 0.846) enrichment among pregnant women.  
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Figure 2.1 legend 
Erythrocyte PC-ARA among third-trimester pregnant consuming 480 (n = 13) or 930 
(n = 13) mg choline/day under controlled conditions for 12 weeks. Statistical analyses 
were performed with linear mixed models that included baseline plasma PC-ARA as a 
covariate; plotted data are predicted means and 95% confidence intervals derived from 
linear mixed models. *indicates PC-ARA enrichment changed (P < 0.01) from week 6 
to study-end. Abbreviations: ARA, arachidonic acid; PC, phosphatidylcholine 
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Nonpregnant women 
Erythrocytes: After controlling for baseline values and covariates, nonpregnant 
women consuming 930 mg choline/d had greater (P = 0.011) erythrocyte PC-DHA 
than nonpregnant women consuming 480 mg/d through week 6 and study-end (Figure 
2.2A). While choline intake did not impact (P = 0.131) erythrocyte PC-ARA 
enrichment, nonpregnant women consuming 930 mg choline/d tended (P = 0.096) to 
have greater PC-EPA+DPAs+DTA enrichment than women consuming 480 mg/d. 
Nonpregnant women consuming 930 mg choline/d had lower (P = 0.021) erythrocyte 
PC-linoleic+oleic than women consuming 480 mg/d through week 6 and study-end 
(Figure 2.2B). 
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Figure 2.2 legend 
Erythrocyte PC-DHA (A) and erythrocyte PC-linoleic+oleic (B) among nonpregnant 
women consuming 480 (n = 10) or 930 (n = 11) mg choline/day under controlled 
conditions for 12 weeks. Statistical analyses were performed with linear mixed models 
that included baseline PC-DHA or PC-linoleic+oleic as a covariate; plotted data are 
predicted means and 95% confidence intervals derived from linear mixed models. 
Dissimilar letters indicate differences (P < 0.05) between groups. Abbreviations: 
DHA, docosahexaenoic acid; linoleic+oleic, linoleic acid + oleic acid; PC, 
phosphatidylcholine 
 63 
  
A 
 64 
Plasma: After controlling for baseline values and covariates, choline intake 
level interacted with time (P = 0.006) to influence plasma PC-DHA enrichment 
(Figure 2.3). Nonpregnant women consuming 930 mg choline/d had greater (P < 
0.001) PC-DHA than women consuming 480 mg/d at week 6; however, there was no 
difference (P = 0.470) in PC-DHA enrichment by choline intake level at study-end. 
Plasma PC-DHA decreased (P = 0.035) among nonpregnant women consuming 930 
mg choline/d and increased (P = 0.038) among women consuming 480 mg choline/d 
from week 6 to study-end. Choline intake did not impact plasma PC-ARA (P = 0.978), 
PC-EPA+DPAs+DTA (P = 0.263), or PC-linoleic+oleic (P = 0.606) enrichment 
among nonpregnant women. 
PC:PE ratio 
After controlling for baseline values and covariates, choline intake did not 
impact erythrocyte (P = 0.513–0.542) or plasma (P = 0.399–0.615) PC:PE in pregnant 
or nonpregnant women.  
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Figure 2.3 legend 
Plasma PC-DHA among nonpregnant women consuming 480 (n = 10) or 930 (n = 11) 
mg/d choline under controlled conditions for 12 weeks. Statistical analyses were 
performed with linear mixed models that included baseline PC-DHA as a covariate; 
plotted data are predicted means and 95% confidence intervals derived from linear 
mixed models. Dissimilar letters indicate differences (P < 0.001) between groups. 
*indicates PC-DHA enrichment changed (P < 0.05) from week 6 to study-end. 
Abbreviations: DHA, docosahexaenoic acid; PC, phosphatidylcholine 
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Impact of Pregnancy on Erythrocyte and Plasma PC-fatty acids and PC:PE ratio 
Erythrocytes: After controlling for covariates, physiologic state interacted with 
time (P < 0.001) to influence erythrocyte PC-DHA (Figure 2.4). At baseline pregnant 
women had greater (P = 0.003) erythrocyte PC-DHA enrichment than nonpregnant 
women; however, by week 6 and at study-end there was no difference (P = 0.835) by 
physiologic state. Erythrocyte PC-DHA enrichment increased (P < 0.001) from 
baseline to study-end in both pregnant and nonpregnant groups. Pregnant women had 
lower erythrocyte (P = 0.005) PC-ARA than nonpregnant throughout the study; 
erythrocyte PC-ARA decreased (P = 0.031) from baseline to study-end among all 
women. Erythrocyte PC-EPA+DPAs+DTA and PC-linoleic+oleic enrichment did not 
vary by physiologic group (P = 0.190–0.538) and decreased (P = 0.031–0.033) among 
all women over the course of the study. Figure 2.5 summarizes erythrocyte PC-fatty 
acid distribution at baseline and study-end. 
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Figure 2.4 legend 
Erythrocyte PC-DHA among third-trimester pregnant (n = 26) and nonpregnant 
women (n = 21) consuming a constant choline intake for 12 weeks. Statistical analyses 
were performed with linear mixed models; plotted data are predicted means and 95% 
confidence intervals derived from linear mixed models. Dissimilar letters indicate 
differences (P < 0.01) between pregnant and nonpregnant groups. *indicates PC-DHA 
enrichment changed (P ≤ 0.001) from baseline to study-end. Abbreviations: DHA, 
docosahexaenoic acid; PC, phosphatidylcholine 
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Figure 2.5 legend 
Erythrocyte PC-fatty acids among third-trimester pregnant (n = 26) and nonpregnant 
women (n = 21) at baseline and after consuming a constant choline intake for 12 
weeks. Statistical analyses were performed with linear mixed models; plotted data are 
predicted means and 95% confidence intervals derived from linear mixed models. * 
indicates difference (P < 0.01) between pregnant and nonpregnant groups. (-) and (+) 
at study-end indicate negative or positive change (P < 0.05) from baseline. 
Abbreviations: ARA, arachidonic acid; DHA, docosahexaenoic acid; 
EPA+DPAs+DTA, eicosapentaenoic acid + omega-3 docosapentaenoic acid + omega-
6 docosapentaenoic acid + docosatetraenoic acid; PC, phosphatidylcholine 
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Plasma: After controlling for covariates, physiologic state interacted with time 
(P < 0.001) to influence plasma PC-DHA (Figure 2.6). At baseline pregnant women 
tended to have greater (P = 0.065) plasma PC-DHA than nonpregnant women; 
however, by week 6 and at study-end there was no difference (P = 0.163) by 
physiologic state. Plasma PC-DHA enrichment increased (P ≤ 0.001) from baseline to 
study-end in both pregnant and nonpregnant groups. Pregnant women had lower 
plasma PC-ARA (P < 0.001) and PC-EPA+DPAs+DTA (P < 0.001) than nonpregnant 
women throughout the study; among all women, plasma PC-ARA and PC-
EPA+DPAs+DTA decreased (P = 0.002 and P < 0.001, respectively) from baseline to 
study-end. Physiologic state tended to interact with time (P = 0.068) to influence 
plasma PC-linoleic+oleic. At baseline pregnant women tended to have greater (P = 
0.079) plasma PC-linoleic+oleic than nonpregnant women and this difference became 
significant (P < 0.001) by study-end. Plasma PC-linoleic+oleic did not change (P = 
0.633) from baseline to study-end among pregnant women, but decreased (P = 0.003) 
among nonpregnant women during the same period. Figure 2.7 summarizes plasma 
PC-fatty acid distribution at baseline and study-end. 
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Figure 2.6 legend 
Plasma PC-DHA among third-trimester pregnant (n = 26) and nonpregnant women (n 
= 21) consuming a constant choline intake for 12 weeks. Statistical analyses were 
performed with linear mixed models; plotted data are predicted means and 95% 
confidence intervals derived from linear mixed models. 
§
indicates a borderline 
difference (P < 0.1) between pregnant and nonpregnant groups. *indicates PC-DHA 
enrichment changed (P < 0.01) from baseline to study-end. Abbreviations: DHA, 
docosahexaenoic acid; PC, phosphatidylcholine 
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Figure 2.7 legend 
Plasma PC-fatty acids among third-trimester pregnant (n = 26) and nonpregnant 
women (n = 21) at baseline and after consuming a constant choline intake for 12 
weeks. Statistical analyses were performed with linear mixed models; plotted data are 
predicted means and 95% confidence intervals derived from linear mixed models. 
*indicates difference (P < 0.001) between pregnant and nonpregnant groups. 
§
indicates a borderline difference (P < 0.1) between pregnant and nonpregnant groups. 
(-) and (+) at study-end indicate negative or positive change (P < 0.01) from baseline. 
Abbreviations: ARA, arachidonic acid; DHA, docosahexaenoic acid; 
EPA+DPAs+DTA, eicosapentaenoic acid + omega-3 docosapentaenoic acid + omega-
6 docosapentaenoic acid + docosatetraenoic acid; linoleic + oleic, linoleic acid + oleic 
acid; PC, phosphatidylcholine 
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PC:PE ratio 
 Throughout the study, pregnant women had lower erythrocyte (P < 0.001) and 
plasma (P = 0.015) PC:PE than nonpregnant women. Erythrocyte PC:PE did not 
change (P =  0.546; Figure 2.8A) over the course of the study; however, in plasma, 
physiologic state interacted with time (P = 0.039; Figure 2.8B) to influence the PC:PE 
ratio response.  Among pregnant women, plasma PC:PE decreased (P < 0.001) from 
baseline to study-end; however, among nonpregnant women this ratio did not change 
(P = 1.0). Among pregnant women, both plasma PC and PE increased (P = 0.001–
0.007) from baseline to study-end; however, PC increased by ~11% while PE 
increased by 30%, thus the PC:PE ratio decreased among pregnant women. Among 
nonpregnant women, neither plasma PC (P = 0.796) nor plasma PE (P = 0.705) 
changed from baseline to study-end.  
  
 73 
  
Figure 2.8 legend 
Erythrocyte PC:PE (A) and plasma PC:PE (B) among third-trimester pregnant (n = 
26) and nonpregnant women (n = 21) consuming a constant choline intake for 12 
weeks. Statistical analyses were performed with linear mixed models; plotted data are 
back transformed predicted means and 95% confidence intervals derived from linear 
mixed models. Dissimilar letters indicate differences (P < 0.05) between pregnant and 
nonpregnant groups.
 
§
indicates a borderline difference (P < 0.1) between pregnant and 
nonpregnant groups. *indicates PC:PE ratio changed (P < 0.001) from baseline to 
study-end. Abbreviations: PC, phosphatidylcholine; PE, phosphatidylethanolamine 
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DISCUSSION 
Due to its highly controlled nature, this study offered a unique opportunity to 
examine the interrelationships of choline and lipid metabolism in pregnant and 
nonpregnant women. This analysis compared parameters of choline related lipid 
metabolism among:  (i) third trimester pregnant women consuming 480 or 930 mg 
choline/d; (ii) nonpregnant women consuming 480 or 930 mg choline/d; and (iii) third 
trimester pregnant and nonpregnant women. Three main findings emerged: (i) among 
nonpregnant women, the rise in PC-DHA was augmented by a higher choline intake; 
(ii) supplementary DHA may influence PEMT activity; and (iii) pregnancy was 
associated with changes in choline related lipid metabolism.  
Choline intake influenced PC-DHA among nonpregnant women 
Among nonpregnant women, a higher choline intake yielded greater 
erythrocyte PC-DHA throughout the study and a more rapid increase in plasma PC-
DHA. Changes in erythrocyte PC-fatty acids among women consuming 930 mg 
choline/d suggest that as flux through the PEMT pathway increased (shown by greater 
PC-DHA, Figure 2A and greater (P = 0.096) PC-EPA+DPAs+DTA), flux through the 
CDP-choline pathway concurrently decreased (shown by lower PC-linoleic+oleic, 
Figure 2B). Thus, while the study treatment which included supplementary DHA 
increased erythrocyte and plasma PC-DHA among all nonpregnant women, these 
results indicate a higher choline intake and supplementary DHA acted synergistically 
to yield the greatest enrichment of erythrocyte PC-DHA. 
 A higher choline intake may facilitate increased flux through the PEMT by 
increasing the availability of methyl donors via its metabolite betaine. Indeed, studies 
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using isotopically labeled choline (d9-choline) have confirmed that methyl groups 
derived from the choline molecule are used in converting PE to PC via the PEMT 
pathway (21,22). In addition, a recent animal study found that female mice rely more 
heavily (vs. males) on choline derived methyl groups for the production of PC through 
SAM dependant PEMT (21). 5-methyltetrahydrofolate (5-methyl-THF) is the other 
carrier of labile methyl groups used to generate SAM. In the present study, folate 
status was “supranutritional” among nonpregnant women as evidenced by high serum 
concentrations and urinary excretion of ~40% of daily folate intake (23). Importantly, 
serum 5-methyl-THF did not differ (P = 0.328) by choline intake group. Thus, among 
nonpregnant women, consumption of 930 vs. 480 mg choline/d yielded greater 
erythrocyte PC-DHA and faster enrichment of plasma PC-DHA despite plentiful 5-
methyl-THF, suggesting a unique relationship between increased availability of 
choline derived methyl groups and flux through PEMT.  
DHA as a driver of PEMT 
Consumption of the study DHA supplement increased erythrocyte and plasma 
PC-DHA among pregnant and nonpregnant women regardless of choline intake. The 
use of plasma PC-DHA as an indicator of hepatic PEMT activity has been suggested 
by da Costa et al. (24). Increases in plasma PC-DHA, ~15% and ~48% among 
pregnant and nonpregnant women, respectively, and erythrocyte PC-DHA, ~17% and 
~53% among pregnant and nonpregnant women, respectively, suggests that 
supplementary DHA increases flux through the PEMT pathway. Nobili et al. (25) 
found supplementary DHA improved liver steatosis in children with NAFLD, which 
supports the hypothesis that increased DHA drives PEMT activity, i.e. as a substrate, 
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supplementary DHA may increase PEMT pathway activity, and in the case of Nobili 
et al. (25), improve dysfunctional VLDL formation associated with NAFLD.  
Although improved and/or increased VLDL formation via increased PEMT 
activity among patients with NAFLD may reduce steatosis, it is not clear that such 
changes in hepatic lipid metabolism would benefit healthy individuals (26). In the 
present study, study-end plasma PC-DHA was not correlated (Pearson coefficient, 
0.199; P = 0.387) with study-end LDL in nonpregnant women, suggesting increased 
PEMT pathway activity altered the make-up but not quantity of VLDL formed among 
these healthy women. Interestingly, among pregnant women at study-end, plasma PC-
DHA was positively correlated (Pearson coefficient, 0.499; P = 0.010) with study-end 
LDL; however, this relationship is likely not caused by supplementary DHA 
increasing PEMT activity. Other mechanisms related to pregnancy induced 
hyperlipidemia, including increased adipose lipolysis, lead to the markedly increased 
VLDL production known to occur during the third-trimester of pregnancy (27). 
Choline related lipid metabolism during pregnancy 
Pregnancy impacted several parameters of choline related lipid metabolism 
including erythrocyte and plasma PC-fatty acid enrichment and PC:PE. As PC-DHA is 
primarily produced via the PEMT pathway, the higher PC-DHA in both erythrocytes 
and plasma at baseline among pregnant women is consistent with upregulated PEMT 
related to elevated estrogen. Pregnancy induced upregulation of PEMT may explain 
why choline intake did not impact erythrocyte or plasma PC-DHA enrichment among 
this group of pregnant women and why erythrocyte and plasma PC-DHA enrichment 
increased less (erythrocyte: 17% vs. 53% and plasma 15% vs. 48%) than enrichment 
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among nonpregnant women consuming the same DHA supplement. That is, if PEMT 
was already upregulated at baseline (i.e. week 27 gestation), it is possible that the 
capacity of choline derived methyl donors and/or additional DHA substrate to 
influence PC biosynthesis via PEMT was reduced. Nevertheless, elevated activity of 
the PEMT pathway, a significant consumer of SAM (28), underscores the increased 
demand for methyl groups during pregnancy. Additional studies are needed to 
examine whether a higher choline intake may enhance PEMT activity and PC-DHA 
enrichment at early stages in gestation. 
Both erythrocyte and plasma PC:PE were lower among third-trimester 
pregnant women as compared with nonpregnant women. It is of note that neither these 
differences nor the decrease of plasma PC:PE observed among pregnant women were 
not modified by a higher choline intake. This indicates that the altered PC:PE ratio 
during pregnancy is not governed by choline intake/availability and may be due to 
conditions associated with this physiologic state such as insulin resistance (29), 
changes in PE biosynthesis (30), and/or reduce hepatic lipase activity (31). At this 
time it is unclear whether the reduced PC:PE ratio during pregnancy has functional 
consequences and it is unknown for how long the lower PC:PE ratio persists after 
parturition.  
Conclusions 
Increasing the level of circulating PC-DHA is often desirable among pregnant 
and nonpregnant women. The strong specificity for PC-DHA generation via the SAM 
dependant PEMT pathway increases the use of and demand for methyl groups, with 
perhaps an explicit requirement for methyl groups derived from choline. Thus, efforts 
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to better understand and/or improve DHA nutriture should fully consider factors 
influencing the PEMT pathway, including methyl donors such as choline.   
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CHAPTER 3 
Comparison of microbiological assay and LC-MS/MS for quantification of folates 
in serum, urine, and breastmilk 
 
ABSTRACT 
Background: The comparison of the microbiological assay (MA), a well established 
method for total folate quantification, and more recently developed liquid 
chromatography dual mass spectrometry (LC-MS/MS) techniques that quantify 
individual folate species is of methodologic interest.  
Methods: Serum, urine, and breastmilk samples collected over the course of a 
controlled feeding study were subjected to MA total folate quantification. 5-
methyltetrahydrofolate (5-methyl-THF) and folic acid (FA) were quantified via LC-
MS/MS in the same samples. Bland Altman limits of agreement (LoA) calculations 
were performed to compare total folate measured via MA and the sum of 5-methyl-
THF and FA measured via LC-MS/MS. 
Results: The LoA mean differences (95% intervals) between MA total folate and the 
sum of 5-methyl-THF + FA measured in serum, urine, and breastmilk were -1.0 
ng/mL (4.5, -6.6); 54.8 µg/day (260.0, -150.5 µg/day); and 20.2 ng/mL (44.6, -4.2 
ng/mL), respectively, with MA as the reference value. MA and LC-MS/MS values 
were correlated; however, measurements from the two methods were significantly 
different for all three sample types. Differences between MA and LC-MS/MS methods 
in urine demonstrated a concentration dependant relationship. 
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Conclusions: In fasted serum, total folate measured via MA is comparable to the sum 
of 5-methyl-THF + FA measured via LC-MS/MS. Larger differences between MA 
and LC-MS/MS measurements in urine and breastmilk indicate the presence of  
additional folate species. Recommendations for improving the agreement of MA and 
LC-MS/MS methods in urine and breastmilk include monitoring of 5-methyl-THF-
diglutamate in urine samples and extracting folate from > 4 mL breastmilk for 
improved sensitivity.   
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BACKGROUND 
The microbiological assay (MA) has been described as the “gold standard” for 
quantification of total folate in biological samples, i.e., the sum of all biologically 
active folate forms; however, more recently developed liquid chromatography dual 
mass spectrometry (LC-MS/MS) methods are appealing because individual folate 
species, e.g., 5-methyltetrahydrofolate (5-methyl-THF) and folic acid (FA), can be 
measured. Therefore, it is of interest whether the sum of individual folate species 
measured via LC-MS/MS is equivalent to total folate measured via MA (1). Prior 
studies (2) have compared serum folate concentrations quantified via MA and LC-
MS/MS; however, comparison of MA and LC-MS/MS folate quantification methods 
have not been published for urine or breastmilk samples. 
The Bland-Altman Limits of Agreement Method (LoA) is an accepted means 
by which to evaluate the agreement of two methods measuring the same quantity (3). 
Using pairs of measurements (i.e., one value per method), LoA generates the mean 
difference between the two methods and an interval based on the standard deviation 
that contains 95% of pairs; the measurement pairs, mean difference, and 95% interval 
can also be represented graphically (3). In this study, 5-methyl-THF and FA were 
quantified in serum, urine, and breastmilk using LC-MS/MS methods, and total folate 
was quantified in the same samples using the MA. The Bland-Altman LoA method 
was used to compare the sum of 5-methyl-THF + FA to the total folate value, using 
MA total folate as the reference value.  
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MATERIALS AND METHODS 
Samples 
 MA and LC-MS/MS measurements were performed with serum, urine, and 
breastmilk samples collected during a 10-12 week controlled feeding study conducted 
in women of childbearing age described in detail elsewhere (4,5). 
Microbiological assay measurements 
The MA (6) with Lactobacillus casei (ATCC 7469) as the test organism and 
10 ng/mL FA (Sigma) as the standard calibrator was used to determine total folate in 
serum, urine, and breastmilk. Breastmilk samples were subjected to trienzyme 
digestion as described in West et al. (5)  prior to measurement via MA. The 
coefficients of variance (CVs) were calculated using a positive quality control sample 
of each analyte. MA intra-assay CVs were < 10%. MA inter-assay CVs were as 
follows: serum, whole blood, and breastmilk, <10%; urine and dietary folate, <13%.  
LC-MS/MS measurements 
5-methyl-THF and FA were quantified using LC-MS/MS stable-isotope 
dilution methods as described in West et al. (5). Briefly, serum, urinary, and 
breastmilk extracts were prepared using solid phase extraction clean-up methods on a 
12-port vacuum manifold (J.T. Baker, Inc.). Standard curves were prepared from 5-
methyl-THF (Sigma) and FA (Sigma) stock solutions and internal standard solutions 
were prepared using 
13
C-5-methyl-THF and 
13
C-FA (Merck Eprova, Switzerland) as in 
Pfeiffer et al. (2). Serum and breastmilk 5-methyl-THF and FA were quantified with a 
TSQ Quantum mass spectrometer (Thermo, San Jose, CA) equipped with a 
refrigerated Accela autosampler (Thermo) and Accela pump with degasser (Thermo). 
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Urinary 5-methyl-THF and FA were quantified with a a LCQ Advantage Max mass 
spectrometer (Thermo) equipped with a refrigerated Surveyor autosampler (Thermo) 
and Surveyor pump with degasser (Thermo). Intra- and inter-assay CVs were <10% 
and <15%, respectively.  
Statistical analysis 
Bland-Altman LoA calculations and statistics were performed with Microsoft 
Excel 2007 and IBM SPSS software (version 19; SPSS Inc, Chicago, IL) as described 
in (3,7) correcting for multiple observations per individual (7). 
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RESULTS 
Serum: Three different samples from 47 participants (141 pairs) were used to 
calculate the serum LoA . The mean difference (95% interval) between serum total 
folate measured via MA and serum 5-methyl-THF + FA measured via LC-MS/MS 
was -1.0 ng/mL (4.5, -6.6) (Figure 3.1A); although very close, this difference was 
significant (P < 0.001). The 141 pair Pearson correlation was 0.96 (P < 0.001). 
Urine: Three different samples from 75 participants (225 pairs) were used to 
calculate the urine LoA. The mean difference (95% interval) between urinary total 
folate measured via MA and urinary 5-methyl-THF + FA measured via LC-MS/MS 
was 54.8 µg/day (260.0, -150.5 µg/day) (Figure 3.1B); this difference was significant 
(P < 0.001). Due to the extreme range of urinary folate values and the appearance of a 
concentration dependant difference between the methods, an additional LoA graph 
using log-transformed data was generated (Figure 3.1C) (3). Figure 3.1C illustrates the 
concentration dependant relationship (y = -0.23x + 0.69 ng/mL, r
2
 =0.32) where 
measurements of greater urinary folate excretion had better agreement, i.e. the mean 
difference between the MA and LC-MS/MS methods was closer to 0 for samples with 
greater folate concentrations. MA and LC-MS/MS measurement pair averages (the 
mean MA and LC-MS/MS x-axis coordinates in LoA figures) were positively 
correlated with the proportion of FA to MA total folate (rho = 0.728, P < 0.001) and 5-
methyl-THF to MA total folate (rho = 0.272, P < 0.001). In other words, as 5-methyl-
THF and FA made up a greater proportion of urinary folate, the sum of the LC-
MS/MS measurement matched the total folate measurement more closely (Figure 
3.1C). The 225 pair Pearson correlation was 0.87 (P < 0.001). 
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Breastmilk: Three different samples from 28 participants (84 pairs) were used 
to calculate the LoA. The mean difference (95% interval) between breastmilk total 
folate measured via MA and breastmilk 5-methyl-THF + FA folate measured via LC-
MS/MS was 20.2 ng/mL (44.6, -4.2 ng/mL) (Figure 3.1D); this difference was 
significant (P < 0.001). The 84 pair Pearson correlation was 0.88 (P < 0.001). 
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Figure 3.1legend 
Bland-Altman Limit of Agreement (LoA) plots for serum (A); urinary (B); log-
transformed urinary (C); and breastmilk (D) MA and LC-MS/MS measurements. LoA 
plots were generated with pairs (A = 141; B = 225; C = 225; D = 84) consisting of one 
MA total folate measurement and one LC-MS/MS 5-methyl-THF + FA measurement. 
Solid horizontal lines indicate mean difference of total folate measured via MA and 5-
methyl-THF + FA measured via LC-MS/MS. Dashed horizontal lines indicate interval 
that contains 95% of points. The trend line in (C) indicates a concentration dependant 
relationship between the magnitude of urinary folate excretion and the 
agreement/difference of MA vs. LC-MS/MS method.  
Abbreviations: 5-methyl-THF, 5-methyltetrahydrofolate; FA, folic acid; MA, 
microbiological assay; LoA, Bland-Altman Limit of Agreement plot; LC-MS/MS, 
liquid chromatography-dual mass spectrometry 
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DISCUSSION 
In serum samples, total folate measured via MA and 5-methyl-THF + FA 
measured via LC-MS/MS match well, although the sum of folate species measured via 
LC-MS/MS was significantly greater than MA total folate. In contrast, Pfeiffer et al. 
found that serum total folate measured via MA was significantly greater than the sum 
of serum 5-methyl-THF, FA, and 5-formyltetrahydrofolate (5-formyl-THF) measured 
via LC-MS/MS; however, the difference was dependent upon the folate species used 
to calibrate the MA (2). Pfeiffer et al. found that 2.5–4.4% of non-fasted serum folate 
was present as 5-formyl-THF (2); the amount of 5-formyl-THF in fasted serum in the 
present study is not known. Despite the small differences between methods, this study 
confirms that the vast majority of fasted serum folate is present as 5-methyl-THF. 
For urine and breastmilk samples, MA concentrations were consistently higher 
than the sum of 5-methyl-THF + FA measured via LC-MS/MS indicating the 
existence of additional folate species. Although breastmilk samples were incubated for 
5 hours with an excess of folate conjugase (2 mL conjugase per 4 mL milk), it is 
possible that polyglutamate 5-methyl-THF remained in appreciable amounts. In an 
attempt to reconcile breastmilk MA and LC-MS/MS measurements, 5-methyl-THF-
diglutamate and 5-formyl-THF were monitored for during LC-MS/MS quantification; 
however, neither was found in quantifiable amounts (data not shown). Thus, it is 
possible that some amount of 5-methyl-THF remained in polyglutamate form after 
trienzyme digestion and/or a larger volume of breastmilk ( >4 mL) must be digested in 
order to detect and quantify other breastmilk folate species via this LC-MS/MS 
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method. Interestingly, preliminary results indicate 5-methyl-THF-diglutamate is 
present in quantifiable amounts in urine. 
Conclusions 
As compared using the Bland-Altman LoA, the sum of 5-methyl-THF and FA 
measured via LC-MS/MS is comparable to total folate measured via MA in fasted 
serum samples. Greater total folate measured via MA in urine and breastmilk indicate 
the existence of additional folate species. Recommendations for improving the 
agreement of MA and LC-MS/MS methods in urine and breastmilk include 
monitoring of 5-methyl-diglutamate in urine samples and extracting folate from > 
4mL breastmilk for improved LC-MS/MS sensitivity.  
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AFTERWORD 
The overarching aim of this research was to elucidate aspects of folate and 
choline metabolism and utilization for the refinement of intake guidelines and 
strategies. Highlighted findings along with potential applications of this research are 
discussed below  
Project 1: Folate status response to a controlled folate intake among nonpregnant, 
pregnant, and lactating women 
Result highlights with implications and applications 
The findings of this study have several implications for the advancement of 
folate intake guidelines and strategies. First, consumption of a FA-containing prenatal 
supplement plus normal mixed diet yielded supranutritional folate status, i.e. high 
serum folate concentrations and urinary folate excretion representing 9–43% of total 
folate intake, regardless of physiologic state. Notably, the increased utilization of 
/demand for folate during pregnancy and lactation was evident only in urinary folate 
excretion which was reduced in these physiologic states. In the current context of 
population wide folate sufficiency, this research will be useful for future folate DRI 
committees in considering whether the definition of adequacy should include the 
prevention of excess folate excretion/loss as is the case for the Vitamin C DRIs.  
Perhaps the most important finding with implications for refinement of folate 
intake guidelines and strategies is that consumption of the study folate dose increased 
breastmilk FA concentrations but not total folate concentrations among participants 
that were not consuming a supplement prior to study enrollment. This result suggests 
that consumption of a FA-containing supplement (with underlying supranutritional 
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status) leads to the displacement of physiologic forms of folate from breastmilk by 
FA, which may be a less bioavailable folate form when bound to the human milk 
folate binding protein. Thus this research, in addition to informing the quantity of 
folate in prenatal supplements, indicates that the form of folate (i.e. FA vs. 5-methyl-
THF) used in prenatal supplements and/or supplements produced for women of 
reproductive age should be revisited.  
Project 2: The influence of choline intake and pregnancy on phosphatidylcholine 
docosahexaenoic acid enrichment among third-trimester pregnant and nonpregnant 
women 
Result highlights with implications and applications 
The results of this study have implications for both choline and DHA intake 
recommendations. First, among nonpregnant women, a higher choline intake yielded 
greater erythrocyte PC-DHA and a faster increase in plasma PC-DHA. Thus, the 
relationship between choline intake and erythrocyte and plasma PC-DHA enrichment 
among nonpregnant women in this study warrants the use of PC-DHA as a functional 
indicator of choline metabolism in this population. Second, third-trimester pregnancy 
was associated with alterations in choline related lipid metabolism which indicated an 
upregulation of the SAM-dependant PEMT PC biosynthetic pathway during the third 
trimester and increased demand for methyl donors during pregnancy. Further research 
is needed to determine whether an increased choline intake may exert a similar effect 
in increasing PC-DHA among pregnant women during the first and second trimesters 
of pregnancy when hepatic lipid metabolism and PEMT activity may more closely 
resemble that of nonpregnant women. Overall, these findings (along with others from 
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this study) will provide important data for revising the choline DRIs as well as 
generate hypotheses that further elucidate choline utilization and requirement among 
women of reproductive age.  
The role of the SAM dependant PEMT pathway in DHA status and 
metabolism is underscored by this research. Findings of this study suggest a 
synergistic relationship between choline intake and DHA supplementation in 
enhancing DHA status in nonpregnant women, a result that may also hold true for 
pregnant women early in gestation. Thus, research aimed at improving DHA intakes 
and status may also consider the role methyl donor intake and status play in supporting 
the distribution of DHA to peripheral tissues and fetus in nonpregnant and pregnant 
women.  
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APPENDIX A 
Genetic Variation: Impact on folate (and choline) bioefficacy
1
 
 
ABSTRACT 
Folate and choline are water-soluble micronutrients that serve as methyl donors in the 
conversion of homocysteine to methionine. Inadequacy of these nutrients can disturb 
one-carbon metabolism as evidenced by alterations in circulating folate and/or plasma 
homocysteine.  Among common genetic variants that reside in genes regulating folate 
absorptive and metabolic processes, homozygosity for the MTHFR 677C>T variant 
has consistently been shown to have robust effects on status markers.  This paper will 
review the impact of genetic variants in folate-metabolizing genes on folate and 
choline bioefficacy.  Nutrient-gene and gene-gene interactions will be considered 
along with the need to account for these genetic variants when updating dietary folate 
and choline recommendations. 
  
                                                 
1
 Published in the International Journal for Vitamin and Nutrition Research, 
2010;80:319–29, see Appendix C for inclusion authorization. 
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INTRODUCTION 
Elucidating how nutrients are digested, absorbed, and metabolized in the 
human body is a fundamental endeavor of nutritional science. Nutrient bioavailability 
is considered to be a function of absorptive and metabolic processes that are 
influenced by such factors as nutrient form, dietary intake, and individual genetic 
variation [1] [2]. Other concepts that fall under the broader umbrella of bioavailability, 
as summarized in Gregory JF [2], are:  
 Bioaccessibility: fraction available for absorption after release from food 
matrix 
 Bioconversion/bioefficacy: fraction of absorbed nutrient converted to the bio-
active form 
 Functional bioefficacy: fraction of nutrient that impacts a functional parameter 
Folate, a water-soluble B-vitamin, is widely recognized for its role in preventing 
neural tube defects (NTDs), its inverse relationship with numerous chronic diseases 
(i.e. coronary heart disease, stroke, cancers, osteoporosis, and dementia) and its 
usefulness as a chemotherapeutic target. The health importance of choline, a "quasi" 
essential micronutrient commonly grouped with the B-vitamins, is less known; 
however its effects on fetal development and programming [3], non-alcoholic fatty 
liver [4] [5] [6], and its intermingling with folate are attracting attention.  
 Folate and choline intersect at the metabolic network involved in the transfer 
of one-carbon units, referred to as one-carbon metabolism, which is required for the 
biosynthesis of nucleotides, the interconversions of select amino acids, and cellular 
methylation [7]. Homocysteine, formed in the methionine cycle, is an indicator of 
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cellular methylation distress (when elevated) and is associated with a plethora of 
health derangements. Methyl groups from folate or the choline derivative, betaine, can 
be used to convert homocysteine to methionine. In subsequent reactions, the nutrient-
derived methyl group can be donated by S-adenosylmethionine (SAM) to acceptor 
molecules with effects on lipid metabolism, neurotransmitter biosynthesis and 
degradation, energy homeostasis, and gene expression and stability (i.e., DNA and 
histone methylation) (Figure A.1). Phosphatidylethanolamine N-methyltransferase 
(PEMT), a main consumer of SAM, catalyzes the sequential methylation of 
phosphatidylethanolamine to phosphatidylcholine (PtdCho) and provides a route for 
de novo synthesis of choline following its hydrolysis from PtdCho. As S-
adenosylhomocysteine is a product of all SAM-dependent methyltransferases, the 
PEMT pathway is also a main producer of homocysteine (Figure A.1).    
 Folate bioefficacy can be assessed by measurements of serum/plasma and RBC 
folate concentrations, well-established markers of folate status [8]. 5-methyl-
tetrahydrofolate (THF) is the main folate form in blood and its polyglutamated 
derivative is the principal bioactive form in tissue. Under normal physiologic 
conditions, circulating folate concentrations reflect the fraction of absorbed nutrient 
that is available to tissue and that can be converted to bioactive co-enzymes. Plasma 
total homocysteine (tHcy) concentration reflects folate availability for homocysteine 
remethylation to methionine and thus may be considered an indicator of functional 
folate bioefficacy [9].    
 Driven by the goal of discovering genetic polymorphisms that impact NTD 
development, homocysteine disposal, and the toxicity/efficacy of antifolate drugs, 
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genetic variation within folate-metabolizing genes has been widely studied over the 
past decade. From this body of literature, and more targeted studies, the impact of 
candidate genes and their polymorphisms on folate (and choline) bioefficacy can be 
examined. This paper provides examples of polymorphisms in folate-metabolizing 
genes that can impact folate (and choline) bioefficacy and explores the need to 
consider these variants when updating dietary recommendations. 
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Figure A.1: Folate-metabolizing genes, with common genetic variants, that may 
impact folate (and choline) bioefficacy. Abbreviations: BHMT- betaine:homocysteine 
methyltransferases; Cob(I)- cob(I)alamin; Cob(II)- cob(II)alamin; Cob(III)- 
methylcob(III)alamin; DHF- dihydrofolate; DHFR- dihydrofolate reductase; DMG- 
dimethylglycine; dUMP- deoxyuridine monophosphate; FA- folic acid; MT- generic 
methyltransferases; MTHFD1- methylenetetrahydrofolate dehydrogenase; MTHFR- 
5,10-methylenetetrahydrofolate reductase; MTR- methionine synthase; MTRR- 
methionine synthase reductase; PEMT- phosphatidylethanolamine N-
methyltransferase; PtEth- phosphatidylethanolamine; PtCho- phosphatidylcholine; 
RFC- reduced folate carrier; SAH- S-adenosyl homocysteine; SAM- S-adenosyl 
methionine; SHMT- serine hydroxymethyltransferase; THF- tetrahydrofolate; TS- 
thymidylate synthase 
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CANDIDATE GENES AND THEIR VARIANTS  
Methylenetetrahydrofolate reductase (MTHFR)  
MTHFR catalyzes the irreversible reduction of 5,10-methylene-THF to 5-
methyl –THF (Figure A.1) and thereby plays a critical role in regulating one-carbon 
flux between nucleotide biosynthesis and cellular methylation. Moreover, as the 
enzyme producing the main form of folate in blood, MTHFR directly impacts 
circulating folate concentrations. The 677C>T variant allele in the MTHFR gene has 
garnered prodigy-like status over the past decade with approximately 300 human 
papers published per year on this single nucleotide polymorphism (SNP ) (or ~ 75% of 
all publications on variants of genes in folate metabolism) [10]. In addition to having 
robust independent effects on folate status and health biomarkers, the MTHFR variant 
677T allele frequently interacts with other one-carbon metabolizing SNPs to affect 
folate and choline status biomarkers. 
MTHFR 677C>T 
Discovered in 1995, this non-synonymous exonic SNP (rs1801133) is the most 
common genetic cause of mild hyperhomocysteinemia and is associated with a 35 or 
65% loss in enzyme activity when one or two T alleles are present respectively [11] 
[12].  The 677C>T polymorphism causes a substitution of valine for alanine in the 
protein's catalytic domain and yields a thermolabile enzyme that is more likely to 
dissociate from its riboflavin derived FAD cofactor [13] [14]. The likelihood of having 
one or two copies of the 677C>T allele varies by ethnicity and geographic location 
[15] [16]. Within the United States, the prevalence of 677TT genotype averages 11% 
but is approximately 20, 12, and 1% among Hispanics, whites, and blacks, 
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respectively [17]. Worldwide, European, Asian, and African population prevalence of 
the 677TT genotype ranges from 4-20, 12- 30, and 0-4%, respectively [18]. 
Epidemiologic and controlled experimental studies consistently demonstrate lower 
folate status among individuals with the 677TT genotype especially when folate status 
is compromised.     
 NHANES III data that pre-dates folic acid fortification of the food supply in 
the United States reported 22% lower serum folate and 25% higher tHcy in those with 
the 677TT versus 677CC genotype [17]. Among an adult Danish population, the 
677TT genotype increased the likelihood of low serum folate by over two times (<6.8 
nmol/L; OR 2.24, P<0.001) [19]. Similarly, in an adult Norwegian population, the 
677TT genotype is associated with a 32% increase in tHcy, a 29% decrease in serum 
folate, and a 10% reduction in the choline derivatives, betaine and dimethylglycine as 
compared to the 677CC genotype [20]. Although homozygosity for the 677T allele 
exerts the strongest effect on folate biomarkers, even a single copy of the 677T allele 
is associated with reduced folate status [17] [19] [20]. 
 Highly controlled dose-response intervention studies have demonstrated a 
higher folate requirement in adults with the MTHFR 677TT genotype. Serum folate 
concentrations in Hispanic premenopausal women with the 677TT genotype were 
significantly lower throughout folate depletion (135 μg/day as dietary folate 
equivalents, DFEs) and during folate repletion with 400 μg DFE/day compared to 
those with the 677CC genotype [21]. These results paralleled a similar study 
conducted in non-Hispanic premenopausal women in which the 677TT genotype 
resulted in lower serum folate (pre- and post-repletion) and lower post-repletion RBC 
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folate [22].  In men, consumption of the folate RDA, 400 μg DFE/day, for 12 weeks 
yielded significantly lower serum folate and three times higher plasma tHcy in the 
677TT versus the 677CC genotype [23]. 
 The effects of genetic polymorphisms on folate bioefficacy can interact with 
nutrient intakes of folate, choline, vitamin B12, vitamin B6, and/or riboflavin [24] [25] 
[26]. The most striking example is in the case of MTHFR 677C>T and folate.  
Although lower serum folate concentrations were observed in women with the 
MTHFR 677TT genotype consuming either 135 or 400 µg DFE/day as discussed 
above [21], no differences in serum folate were detected between MTHFR C677T 
genotypes in another treatment arm consuming 800 μg DFE/day. Other studies have 
also shown that with an intake of ≥600 μg DFE/day, serum folate concentrations did 
not significantly differ between the MTHFR C677T genotypes [27] [28].   
MTHFR 1298A>C 
A second common non-synonymous SNP in the MTHFR gene, 1298A>C 
(rs1801131), causes the substitution of an alanine for glutamate in the regulatory 
domain of the MTHFR protein [29] [30].  The 1298A>C variant has been shown to 
reduce MTHFR enzyme activity in human lymphocytes; however, not to the extent 
677C>T diminishes MTHFR activity [29] [30].   Notably, experiments using bacterial, 
mammalian, and yeast expression systems have failed to observe a functional impact 
of the 1298A>C SNP [14] [31] [26]. The prevalence of the 1298A>C allele varies by 
geographic region and ethnicity with 10% of whites and ~3.5% in blacks and 
Hispanics having the 1298CC genotype in the US [17]. Among European, Asian, and 
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African populations, prevalence of the 1298CC genotype ranges from 4-13, 2-5, and 
0-1%, respectively [18].    
 The impact of the MTHFR1298A>C SNP on folate status is ambiguous.  The 
majority of studies, including the NHANES III study described above, have found no 
significant associations between the 1298A>C variant and markers of folate status 
[17] [19] [30]. However, a large scale epidemiologic study found that compared with 
the homozygous wild type genotype, the 1298CC genotype was associated with a 5% 
increase of tHcy and a decrease of 9% and 3% for serum folate and betaine, 
respectively [20]. Thus, while there is evidence that the 1298CC genotype impacts 
folate bioefficacy, the current body of evidence indicates that the MTHFR 677TT 
genotype has a much greater effect on both metabolic bioefficacy, (i.e. generation of 
5-methyl-THF) and functional bioefficacy (i.e. plasma tHcy concentrations). 
MTHFR Haplotypes: 677C>T + 1298A>C 
The 677C>T and 1298A>C SNPs are rarely found on the same allele (i.e. these 
SNPs are in strong linkage disequilibrium) [30] [32] which implies that the metabolic 
impact of the MTHFR A1298C genotype should be considered within the context of 
the MTHFR C677T genotype. A MTHFR genotype meta-analysis calculated 
Caucasian population MTHFR haplotype frequencies as follows:  677C/1298A, 37%; 
677C/1298C, 31%; 677T/1298A, 32%; and 677T/1298C, 0.23-0.34% [32]. Notably, 
heterozygous MTHFR genotypes are of interest due to widespread prevalence and 
evidence of functional consequences (i.e., penetrance).  The 677CT plus 1298AC 
genotype is associated with reduced MTHFR enzyme activity, reduced plasma folate, 
and increased tHcy [29] [30] [33]. A large scale epidemiologic study (n=10,034) 
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ordered MTHFR genotypes by decreasing levels of serum folate as follows: 
677CC/1298AA (highest) > 677CC/1298AC > 677CC/1298CC ~ 677CT/1298AA > 
677CT/1298AC > 677TT/1298AA (lowest) [33]. After comparing these genotypes 
with a model that included six MTHFR protein configurations of varying functionality 
and stability, the investigators found that the least functional/stable enzyme 
configurations corresponded with particular genotypes and lower serum folate 
concentrations [33]. These results indicate that although the effect of the 
heterozygosity for the 1298A>C and 677C>T SNPs do not always emerge as 
significant predictors of status endpoints, depending on genotype and folate exposure, 
these genetic polymorphisms can have an important impact on MTHFR enzyme 
function and folate bioefficacy. 
Reduced Folate Carrier (RFC) 
RFC, the product of the SLC19A1 gene, is a bidirectional folate transporter 
that is ubiquitously expressed and represents a main route of folate entry into most 
systemic tissues. However, despite being expressed in enterocytes, RFC does not 
appear to play a significant role in intestinal folate absorption. Instead, absorption of 
folate across the intestinal epithelium is mediated by the more recently identified 
proton-coupled folate transporter (PCFT) [34]. Mutations in PCFT are a cause of 
hereditary folate malabsorption [35]; however, putative common PCFT genetic 
variants have not yet been reported. 
 RFC spans the plasma membrane 12 times and has a relatively high 
affinity for reduced folates, including 5-methyl-THF, but a low affinity for oxidized 
synthetic folic acid. A common SNP resides at position 80 in exon 2 of RFC which 
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changes a guanine to adenine (RFC 80G>A; rs1051266); although 80A>G is also 
reported [18] [36]. The 80G>A SNP causes a substitution of histidine for arginine and 
is predicted to reside in the first transmembrane domain, a region implicated as 
important to carrier function [37]. Among European, Asian, and African populations, 
prevalence of the 80GG genotype has been reported to be ~29, ranging from 20-30, 
and ~13%, respectively [18]. Existing data show null [36] [20] or nominal [38] effects 
of the RFC 80AA genotype on markers of folate status including serum folate, RBC 
folate and plasma homocysteine. A study conducted in Ireland reported higher RBC 
folate in women homozygous for the variant 80A allele; nevertheless, the genotype 
explained only a minor percentage, 5%, of RBC folate variation [38]. Some studies 
report an interaction between the RFC G80A and MTHFR C677T genotypes [36] [39] 
[40] but due to discrepancies in nomenclature, the relationship of the interaction is 
unclear. Like MTHFR 1298A>C and MTRR 66A>G (see next section), RFC 80G>A 
SNP in isolation does not appear to have a strong effect but may synergistically 
interact with the MTHFR 677C>T SNP to impact folate bioefficacy.   
MTR & MTRR 
Upon cellular entry, THF is generated from 5-methyl-THF when it is used to 
convert homocysteine to methionine in a reaction catalyzed by the vitamin B-12 
(cobalamin) dependent methionine synthase (MTR) (Figure A.1). MTR-bound 
cob(I)alamin can be methylated by 5-methyl-THF to generate the 
methylcob(III)alamin intermediate which serves as the direct methyl donor in 
conversion of homocysteine to methionine. Alternatively, MTR-bound cob(I)alamin 
can be oxidized to the nonfunctional cob(II)alamin form which is subsequently 
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reduced and methylated to the methylcob(III)alamin intermediate via the action of 
SAM dependent methionine synthase reductase (MTRR) [41].  
 Genetic variation in MTR and MTRR has the potential to interfere with the 
production of methionine and THF thereby disrupting folate homeostasis and 
elevating tHcy [42]. The MTR 2756A>G SNP (rs1805087) results in a glycine for 
aspartic acid substitution and appears to have a potentially protective effect as it is 
associated with reduced tHcy concentrations [20] [42] [43], an effect that is 
independent of the MTHFR C677T genotype. Conversely, the nonsynonymous MTRR 
66A>G SNP (rs1801394) is associated with increased tHcy but only when combined 
with the MTHFR 677TT genotype [17] [43] [44]. Given the high prevalence of the 
MTR 2756G and MTRR 66G variant alleles, 19 and 25-60% [17] [20], these SNPs 
have the potential to impact folate bioefficacy in a large number of individuals. 
DHFR 
Dihydrofolate, a product of thymidylate synthase, is reduced to THF by the 
enzyme dihydrofolate reductase (DHFR) (Figure A.1). Thus, DHFR plays a critical 
role in maintaining the cellular supply of reduced folates required for DNA synthesis. 
Folic acid is an additional substrate of DHFR, which via two consecutive reductions, 
enters the folate cycle as THF. Thus, DHFR is essential for converting folic acid, the 
synthetic folate used in food supply fortification and vitamin supplements, into a form 
that is usable by the body. Given these two functions, polymorphisms in the DHFR 
gene are of considerable interest in the folate bioefficacy discussion. 
 To date, there have been no SNPs identified in the coding region of DHFR; 
however, a 19 base pair deletion (19-bp del) polymorphism  in intron 1 of the DHFR 
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promoter (reference sequence NC_000005.8) results in the loss of a transcription 
factor binding site which may alter protein expression [45]. The 19-bp deletion allele 
is common with measures of the deletion/deletion (del/del) genotype of ~ 17-33% [45] 
[46] [47] [48]. The 19-bp del polymorphism appears to be functional, however, it is 
unclear whether gene expression is increased [47] [49] or decreased [45] [50]. 
 Reports of the association between the 19-bp del variant and folate status have 
also been mixed. One study reported that the homozygous 19-bp del/del and 
heterozygous 19-bp del/wild type genotypes were associated with 14.4 and 2.5% 
reductions in tHcy [46]. Another study that seems to support the former, found that 
among young Irish women the homozygous 19-bp del/del genotype was marginally 
associated with increased RBC and serum folate levels [51]. A third study found 
interactions between the 19-bp del/del genotype, folic acid dose, RBC folate, and 
circulating un-metabolized folic acid [48]. The homozygous 19-bp del/del genotype 
was associated with lower RBC folate on a folic acid dose of <250 ug/d, but higher 
plasma un-metabolized folic acid with a dose of ≥500 ug/d [48]. These findings 
suggest impaired functional capacity of the 19-bp del DHFR enzyme to convert folic 
acid to a physiologic form.   
 Genetic variation in DHFR may contribute to the nearly 5-fold variation in 
DHFR enzyme activity measured in human liver samples (n=6) [52]. Of particular 
note in discussing bioconversion is that the reduction reaction involving synthetic folic 
acid and DHFR was significantly slower than the reduction reaction involving 
physiologic dihydrofolate and DHFR [52]. Although further research is warranted, 
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these findings suggest that the 19-bp del DHFR variant, and perhaps other DHFR 
variants, have the potential to impact folate bioefficacy. 
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GENETIC POLYMORPHISMS AND CHOLINE BIOAVAILABILITY 
The interplay of folate and choline in one-carbon metabolism has been well 
described [7] and recently highlighted by genetic variants in folate-metabolizing genes 
altering biomarkers of choline status.  
Methylenetetrahydrofolate dehydrogenase (MTHFD1) 
The MTHFD1 gene codes for a tri-functional enzyme that enables entry of 
mitochondrial one-carbons into the cytosol with its 10-formylTHF synthetase activity 
and facilitates the interconversions of 10-formylTHF, 5,10-methenylTHF and 5,10-
methyleneTHF with its cyclohydrolase and dehydrogenase activities [53] (Figure A.1).  
A non-synonymous guanine to adenine SNP at nucleotide 1958 prompts the 
substitution of a glutamine for arginine amino acid in the 10-formylTHF synthetase 
domain (MTHFD1 1958G>A; rs2236225) [54]. Prevalence of the variant MTHFD1 
1958AA genotype is 13-22, 0-9, and 3-5% in European, Asian, and African 
populations, respectively [18].  
 Although the 1958G>A SNP has not been associated with impaired folate 
status in epidemiological studies [20] [54], one or two copies of the variant 1958A 
allele increases the risk of exhibiting signs of choline deficiency (i.e. organ 
dysfunction) in response to dietary choline depletion (OR=7, P=0.007) [55]. This risk 
is further enhanced if the choline deficient diet is coupled with a low folate intake.  
Premenopausal women carrying one or two copies of the variant 1958A allele were 
especially susceptible to increased risk of organ dysfunction under these dietary 
regimens (OR=85, P<0.0001). The investigators hypothesized that the variant 1958A 
allele results in a dysfunctional MTHFD1 enzyme which reduces the flow of folate 
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one-carbon units towards homocysteine remethylation. This in turn places a greater 
burden on one-carbon units derived from the choline metabolite betaine, leading to 
choline deficiency. Additionally, it may reduce the pool of SAM that is available for 
denovo biosynthesis of PtdCho through the PEMT pathway. PEMT is upregulated by 
estrogen which enables premenopausal women to make more choline endogenously 
(relative to men and postmenopausal women) [57] [8]. Thus, a dysfunctional 
MTHFD1 may impair the PEMT reaction and contribute to the excess susceptibility of 
premenopausal women with the variant 1958A allele to choline depletion.  
 The tendency for tHcy to increase more in premenopausal women if they had 
the MTHFD1 1958AA genotype [relative to the 1958GA (P=0.033) and 1958GG 
(P=0.085) genotypes supports the hypothesis that the 1958G>A SNP has a functional 
effect on cellular methylation [56]. It should be noted that this effect was only 
observed on a folate restricted diet and disappeared with subsequent folate repletion 
[56]. In vitro studies show the MTHFD1 1958A>G protein is thermolabile with 
reduced enzyme activity; however, added folate restores the 1958A>G protein to wild 
type enzyme activity levels [58]. Collectively, these findings indicate that under 
conditions of sub-optimal folate/choline intake, the MTHFD1 1958A>G SNP impacts 
folate and choline bioefficacy by modulating the availability of 5-methyl-THF. 
MTHFR 
Several studies have shown that MTHFR deficiency alters the metabolism of 
choline [59] [60] [61] [62]. In young men consuming sub-optimal folate intakes along 
with one of four choline intakes (range: 300-2200 mg/d), lower concentrations of 
plasma PtdCho were observed in the 677TT versus CC genotype regardless of choline 
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intake [60]. Diminished PtdCho in the MTHFR 677TT genotype under these dietary 
constraints may arise from increased use of choline as a methyl donor. This working 
hypothesis was recently supported by a tracer study involving a sub-sample of these 
men in which a greater flux of choline towards betaine (and other oxidative products) 
was detected in the MTHFR 677TT [63]. Although, the MTHFR C677T genotype 
modifies choline metabolism in premenopausal women, the relationship is less clear 
likely due to engagement of compensatory mechanisms. For example, in 
premenopausal women that completed a study with constant choline intake of 349 
mg/d and folate depletion and repletion stages ([21] discussed above), plasma PtdCho 
decreased significantly during folate depletion, however, women with the MTHFR 
677TT genotype tended to be resistant to the decline (P=0.089) [59]. When serum 
folate was included as a covariate in the statistical model, MTHFR genotype emerged 
as a predictor of plasma PtdCho (P=0.027) and PtdCho was significantly higher in 
women with the 677TT genotype (P=0.032) [59].  
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DISCUSSION  
Genetic variants in folate metabolizing genes have been associated with risk of 
a variety of diseases, including birth defects, cancer, and cardiovascular disease.  
Mechanisms and causation are yet to be proven; however, proposed pathways 
involving DNA stability and one-carbon partitioning have been suggested [64].  
Implicit in genetic variation and disease risk associations is that genetic 
polymorphisms alter nutrient bioefficacy such that protein and cellular functions are 
altered, ultimately conferring either increased or attenuated disease risk. Although 
there is debate about what can be concluded from associations between common 
genetic polymorphisms in folate-metabolizing genes and disease risk [65] [66], 
stronger conclusions about the impact of genetic polymorphisms on folate bioefficacy 
can be made.   
 Homozygosity for the MTHFR 677C>T variant allele is the most robust 
modifier of folate status markers among the folate-metabolizing SNPs investigated 
thus far. However, the severity of 677TT genotype on markers of folate metabolism 
depends to a large degree on folate intake because relatively high intracellular 
concentrations of folate can stabilize the functional impairment caused by the 677C>T 
SNP. Due mainly to folic acid fortification of the food supply, the average folate 
intake for men and women in the United States is 813 and 724 μg DFE/day, 
respectively [67], which is well above the current US folate RDA for adults (400 μg 
DFE/day) and above the level at which strong effects of the 677TT genotype are 
observed (<600 μg DFE/day). Thus, given current folate intakes in the US (and other 
fortified populations) along with the marginal effects of common genetic variation on 
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folate and choline bioefficacy (reviewed in part herein), it is unlikely that SNPs in 
folate-metabolizing genes, even the MTHFR 677C>T, detrimentally impact folate and 
choline status at the population level. A US epidemiological study examining serum 
folate and tHcy levels pre- and post-folic acid fortification stratified by MTHFR 
C677T genotype reveals as much: those with the 677TT genotype have significantly 
higher tHcy at both time points, however, the difference in means goes from 2.5 
μmol/L pre-fortification to ≤0.7 μmol/L post-fortification [68]. 
 Although there is little evidence that population level folate status is 
compromised by common genetic polymorphisms in folate-metabolizing genes in the 
US, the issue of whether dietary recommendations should consider genetic variation 
remains [69] [70]. Research examining the current RDA of 400 μg DFE/day has 
shown it to be adequate for women with the 677TT genotype [21] [22], yet insufficient 
for men with the 677TT genotype [23]. In a recent study, 34% and 79% of men with 
the 677TT genotype had serum folate concentrations <6.8 nmol/L and tHcy >14 
μmol/L after 12 weeks of consuming the folate RDA [23]. Interestingly, these same 
signs of folate deficiency were exhibited in 16% and 7% of men with the 677CC 
genotype [23].  This small, yet highly controlled study raises uncertainty as to whether 
the current folate RDA, 400µg DFE/day, is sufficient for meeting the requirement of 
97% of men. Using a model that projected folate RDA ranges based on the 677TT 
genotype and different functional effect sizes (5-50%), Robitaille et al. [71] concluded 
that the MTHFR 677TT genotype does not warrant changes to the 1998 folate RDA. 
This type of statistical approach in assessing whether common SNPs affect nutrient 
requirements is highly useful but in this particular case [71], the adequacy of the folate 
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RDA for the MTHFR 677CC genotype is questionable given the results of a metabolic 
study in which folate intake was controlled [23].     
 It has long been recognized that folate metabolism is under genetic control and 
that genetic heterogeneity explains a large percentage (i.e. > 40%) of variation in 
metabolism [8]. Historically, this genetic heterogeneity has been accounted for when 
setting RDAs by adding two coefficients of variation (CV) of 10 percent each to the 
estimated average intake (i.e. EAR x 1.2). However, the assumption of a 10 percent 
CV is based on variation in basal metabolic rate [8] and may not adequately capture 
the impact of genetic variation in folate-metabolizing genes on bioefficacy and 
requirements. The plethora of studies published over the past decade on SNPs and 
aspects of folate metabolism afford the opportunity to refine estimates of variability 
such that effects of genetic background (as well as other factors) could be more 
thoroughly addressed. This type of analysis may in turn alleviate the need to 
individualize dietary recommendations on the basis of genetic sub-groups.   
CONCLUSION 
The impact of genetic variation on folate and choline status markers is well-
studied.  Homozygosity for the variant MTHFR 677T allele is a strong modifier of 
folate (and choline) bioefficacy particularly under conditions of sub-optimal folate 
intake. Gene-gene interactions are also apparent such that certain combinations (i.e. 
MTHFR 677TT and RFC 80GG) may exacerbate metabolic disturbances.  A nutrient 
specific estimate of population wide variability in folate bioefficacy would provide a 
background on which to determine the need to account for functional SNPs (within the 
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context of complex interactions) in revising dietary recommendations for folate and 
choline. 
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Pregnant Women 
Health History Questionnaire 
 
 
Demographic Information 
 
Date:  _______________________________ 
 Month  Day  Year 
 
 
Name:  ____________________________________________________________ 
 First    Last 
 
 
Phone  __________________ ________________     _______________ 
  Home    Cell   Email 
 
Address:  
 _____________________________________________________________ 
 
 _____________________________________________________________ 
 
 _____________________________________________________________ 
   
Age:  _____    Date of Birth:  _________________ 
       Mo.  Day Year 
 
Education Completed: 
   ______High School Graduate ______Master’s Degree 
 
   ______Bachelor’s Degree  ______Doctoral Degree
      
Present Work/Student Status: 
 
 ______Working Full-time  ______Full-time student 
 ______Working Part-time  ______Part-time student 
 ______Not Employed   ______Retired 
 
 
 
 
 
 
 
 136 
 
Pregnancy Information 
 
Gestational Age at Present:   _________________ (weeks)  
  
 
Date of Last Menstrual Period:  _________________  (month/day/year) 
 
Due Date:     _________________  (month/day/year) 
   
 
Anthropometric Data 
 
Height (without shoes)    _______ 
 
Pre-Pregnancy weight (dressed with shoes)  _______ 
 
Current weight (dressed with shoes)   _______  
 
Medical History 
 
Indicate if you have had or currently have any of the following medical problems.  
Check all that apply: 
 
Yes No 
 
___ ___ Alcoholism 
 
___ ___ Cardiovascular Disease (Atherosclerosis / Heart Attack/Stroke) 
 
___ ___ Eye Problems (ie, glaucoma, cataracts, retinopathy) 
 
___ ___ Gall Bladder Disease 
 
___ ___ High Blood Cholesterol 
 
___ ___ High Blood Pressure 
 
___ ___ Intestinal Disorders 
 
___ ___ Kidney Disease 
 
___ ___ Liver Disease 
 
___ ___ Lung Disease 
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___ ___ Neurologic/Seizure Disorder 
 
___ ___ Obesity / Overweight 
 
___ ___ Thyroid Disease 
 
___ ___ Tumors / Cancer – List type: _________________ 
 
___ ___ Ulcers 
 
___ ___ Other – Specify: ________________________________________ 
 
___ ___ Recent surgeries?  If yes, specify: ______________________________ 
 
 
Indicate the prescription/nonprescription medicines you currently use on a regular 
basis. 
Check all that apply: 
 
___ Allergy Medicines/Antihistamines  ___ Antacids 
 
___ Antibiotics     ___ Anti-arrhythmics 
 
___ Anti-inflammatory Agents (i.e. Ibuprofen) ___ Aspirin 
 
___ Asthma Medicines    ___ Beta Blockers 
 
___ Blood Pressure Medicines   ___ Blood Thinners 
 
___ Diabetes Medicines – Specify: ____________________________________ 
 
___ Diuretics     ___ Gout Medicines 
 
___ Heart Medicines – Specify: _______________________________________ 
 
___ Hormones – Specify: ____________________________________________ 
 
___ Seizure Medicines    ___ Thyroid Medicines 
 
___ Medicines interfering with folate metabolism – Specify: ________________ 
 
___ Other – Specify: ________________________________________________ 
 138 
 
 
 
Supplement Use 
Indicate the supplements you currently use on a regular basis. 
Check all that apply. 
 
___ Prenatal Supplement  (name/brand) 
____________________________________________________ 
 
___ Multivitamin/Minerals  ___ Herbs 
 
___ Amino acids    ___ Ergogenic Aids (i.e., creatine) 
 
___ Other-Specify: _____________________________________________ 
 
Activity Status 
 
What would best describe your activity level? 
____ Level 1: Usual daily activities 
____ Level 2: Some form of exercise (i.e., walking, dancing, riding a bike) at least 3 
times per week 
____ Level 3: Vigorous exercise (i.e., singles tennis, running, aerobics, weight 
lifting) at least 3 times/ week. 
 
Beverage Consumption 
 
Indicate the amount and frequency with which you consume the following at present: 
 
  Amt.  Never/Rarely Occasionally Frequently Daily 
  (each)  (5x/yr)  (2-3x/mo.) (2-3x/wk.) 
Beer  _____  _____  _____  _____  _____ 
Liquor  _____  _____  _____  _____  _____ 
Wine  _____  _____  _____  _____  _____ 
Wine Coolers _____  _____  _____  _____  _____ 
Coffee  _____  _____  _____  _____  _____ 
Tea  _____  _____  _____  _____  _____ 
Soda  _____  _____  _____  _____  _____ 
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Lactating Women 
Health History Questionnaire 
 
 
Demographic Information 
 
 
Date:  _______________________________ 
 Month  Day  Year 
 
 
Name:  ____________________________________________________________ 
 First    Last 
 
 
Phone  _________________  ______________ _________________ 
 Home    Cell    Email 
 
Address:  
 ____________________________________________________________ 
 
 ____________________________________________________________ 
 
 ____________________________________________________________ 
   
Age:  _____    Date of Birth:  _________________ 
       Mo.  Day Year 
 
Education Completed: 
   ______High School Graduate  ______Master’s Degree 
 
   ______Bachelor’s Degree  ______Doctoral Degree
      
Present Work/Student Status: 
 
 ______Working Full-time  ______Full-time student 
 ______Working Part-time  ______Part-time student 
 ______Not Employed   ______Retired 
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Pregnancy Information 
 
Due Date:     _________________ (month/day/year) 
   
 
Delivery Date:    _________________  (month/day/year) 
 
Health Insurance Provider: __________________________________ 
 
Total Weight Gained During Pregnancy: _______________________________ 
 
Complications During Pregnancy:   _______ Yes  _______No 
 
If yes, describe: 
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_______________________________________________________________ 
 
Complications During Labor:  _______Yes   ________No 
 
If yes, describe: 
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_______________________________________________________________ 
 
Newborn Information 
 
Date of Delivery:   _______________________________ 
   Month  Day  Year 
 
 
Mode of Delivery (i.e., vaginal or C-section): ________________________________ 
 
Gestational Age:   _______________________________ 
 
Length:   ______________________________ 
 
Weight:  ______________________________ 
 
Head Circumference: ______________________________ 
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Anthropometric Data 
 
Height (without shoes)    _______ 
 
Pre-Pregnancy weight (dressed with shoes)  _______ 
 
Current weight (dressed with shoes)   _______  
 
Medical History 
 
Indicate if you have had or currently have any of the following medical problems.  
Check all that apply: 
 
Yes No 
 
___ ___ Alcoholism 
 
___ ___ Cardiovascular Disease (Atherosclerosis / Heart Attack/Stroke) 
 
___ ___ Eye Problems (ie, glaucoma, cataracts, retinopathy) 
 
___ ___ Gall Bladder Disease 
 
___ ___ High Blood Cholesterol 
 
___ ___ High Blood Pressure 
 
___ ___ Intestinal Disorders 
 
___ ___ Kidney Disease 
 
___ ___ Liver Disease 
 
___ ___ Lung Disease 
 
___ ___ Neurologic/Seizure Disorder 
 
___ ___ Obesity / Overweight 
 
___ ___ Thyroid Disease 
 
___ ___ Tumors / Cancer – List type: _________________ 
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___ ___ Ulcers 
 
___ ___ Other – Specify: ____________________________________________ 
 
___ ___ Recent surgeries?  If yes, specify: ______________________________ 
 
 
Indicate the prescription/nonprescription medicines you currently use on a regular 
basis. 
Check all that apply: 
 
___ Allergy Medicines/Antihistamines  ___ Antacids 
 
___ Antibiotics     ___ Anti-arrhythmics 
 
___ Anti-inflammatory Agents (i.e. Ibuprofen) ___ Aspirin 
 
___ Asthma Medicines    ___ Beta Blockers 
 
___ Blood Pressure Medicines   ___ Blood Thinners 
 
___ Diabetes Medicines – Specify: ____________________________________ 
 
___ Diuretics     ___ Gout Medicines 
 
___ Heart Medicines – Specify: _______________________________________ 
 
___ Hormones (ie, birth control bills) – Specify: 
__________________________________________ 
 
___ Seizure Medicines    ___ Thyroid Medicines 
 
___ Medicines interfering with folate metabolism – Specify: ________________ 
 
___ Other – Specify: ________________________________________________ 
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Supplement Use 
 
Indicate the supplements you currently use on a regular basis. 
Check all that apply. 
 
___ Prenatal Supplement  (name/brand) ________________________________ 
 
___ Multivitamin/Minerals  ___ Herbs 
 
___ Amino acids    ___ Ergogenic Aids (i.e., creatine) 
 
___ Other-Specify: _______________________________________________ 
 
Activity Status 
 
What would best describe your activity level? 
____ Level 1: Usual daily activities 
____ Level 2: Some form of exercise (i.e., walking, dancing, riding a bike) at least 3 
times per week 
____ Level 3: Vigorous exercise (i.e., singles tennis, running, aerobics, weight lifting) 
at least 3 times/ week. 
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InfoNon-Pregnant Women 
Health History Questionnaire 
 
 
Demographic Information 
 
Date:  _______________________________ 
 Month  Day  Year 
 
 
Name:  ____________________________________________________________ 
 First    Last 
 
 
Phone  __________________ ______________      _________________ 
  Home    Cell   Email 
 
Address:  
 __________________________________________________________ 
 
 __________________________________________________________ 
 
 __________________________________________________________ 
   
Age:  _____    Date of Birth:  _________________ 
       Mo.  Day Year 
 
Education Completed: 
   ______High School Graduate ______Master’s Degree 
 
   ______Bachelor’s Degree  ______Doctoral Degree
      
Present Work/Student Status: 
 
 ______Working Full-time  ______Full-time student 
 ______Working Part-time  ______Part-time student 
 ______Not Employed   ______Retired 
 
Number of Children:  ______________ 
 
Number of pregnancies: _____________ 
 
 
 145 
 
 
Anthropometric Data 
 
 
Height (without shoes)   _______ 
 
Current weight (dressed with shoes)  _______  
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Medical History 
 
Indicate if you have had or currently have any of the following medical problems.  
Check all that apply: 
 
Yes No 
 
___ ___ Alcoholism 
 
___ ___ Cardiovascular Disease (Atherosclerosis / Heart Attack/Stroke) 
 
___ ___ Eye Problems (ie, glaucoma, cataracts, retinopathy) 
 
___ ___ Gall Bladder Disease 
 
___ ___ High Blood Cholesterol 
 
___ ___ High Blood Pressure 
 
___ ___ Intestinal Disorders 
 
___ ___ Kidney Disease 
 
___ ___ Liver Disease 
 
___ ___ Lung Disease 
 
___ ___ Neurologic/Seizure Disorder 
 
___ ___ Obesity / Overweight 
 
___ ___ Thyroid Disease 
 
___ ___ Tumors / Cancer – List type: _________________ 
 
___ ___ Ulcers 
 
___ ___ Other – Specify: ________________________________________ 
 
___ ___ Recent surgeries?  If yes, specify: __________________________ 
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Indicate the prescription/nonprescription medicines you currently use on a regular 
basis. 
Check all that apply: 
 
___ Allergy Medicines/Antihistamines  ___ Antacids 
 
___ Antibiotics     ___ Anti-arrhythmics 
 
___ Anti-inflammatory Agents (i.e. Ibuprofen) ___ Aspirin 
 
___ Asthma Medicines    ___ Beta Blockers 
 
___ Blood Pressure Medicines   ___ Blood Thinners 
 
___ Diabetes Medicines – Specify: ____________________________________ 
 
___ Diuretics     ___ Gout Medicines 
 
___ Heart Medicines – Specify: _______________________________________ 
 
___ Hormones – Specify: ____________________________________________ 
 
___ Seizure Medicines    ___ Thyroid Medicines 
 
___ Medicines interfering with folate metabolism – Specify: ________________ 
 
___ Other – Specify: ________________________________________________ 
 
 
Supplement Use 
Indicate the supplements you currently use on a regular basis. 
Check all that apply. 
 
___ Multivitamin/Minerals  ___ Herbs 
 
___ Amino acids    ___ Ergogenic Aids (i.e., creatine) 
 
___ Other-Specify: __________________________________________________ 
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Activity Status 
 
What would best describe your activity level? 
____ Level 1: Usual daily activities 
____ Level 2: Some form of exercise (i.e., walking, dancing, riding a bike) at least 3 
times per week 
____ Level 3: Vigorous exercise (i.e., singles tennis, running, aerobics, weight 
lifting) at least 3 times/ week. 
 
 
Beverage Consumption 
 
Indicate the amount and frequency with which you consume the following: 
 
  Amt.  Never/Rarely Occasionally Frequently Daily 
  (each)  (5x/yr)  (2-3x/mo.) (2-3x/wk.) 
Beer  _____  _____  _____  _____  _____ 
Liquor  _____  _____  _____  _____  _____ 
Wine  _____  _____  _____  _____  _____ 
Wine Coolers _____  _____  _____  _____  _____ 
Coffee  _____  _____  _____  _____  _____ 
Tea  _____  _____  _____  _____  _____ 
Soda  _____  _____  _____  _____  _____ 
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Cornell University  
Informed Consent for Research Involving Human Study Participants 
 
You are being invited to participate in a research study. This form is 
designed to provide you with information about this study. The Principal 
Investigator or representative will describe this study to you and answer 
any of your questions.   
 
Project Title:  
Effect of maternal choline intake on maternal/fetal biomarkers of choline 
status  
 
Investigators: 
Marie Caudill, PhD, RD; Associate Professor, Division of Nutritional Sciences, 
Cornell University 
Eva Pressman, MD. Director of Obstetrics and Maternal-Fetal Medicine, Department 
of Obstetrics and Gynecology, University of Rochester School of Medicine, 
Rochester, New York 
Richard Canfield, PhD. Research Associate, Division of Nutritional Sciences, Cornell 
University 
Barbara Strupp, PhD. Professor, Division of Nutritional Sciences, Cornell University 
Srisatish Devapatla, MD. Director, Special Care Nursery, Chairman- Dept. of 
Pediatrics, Cayuga Medical Center at Ithaca, Ithaca, New York. 
Sandy Saintonge, MD. Assistant Professor of Clinical Public Health and Clinical 
Pediatrics, Weill Cornell Medical College, Attending Physician, New York Hospital 
Queens, Department of Emergency Medicine 
Cydne Perry, PhD. Post-doctoral Associate, Division of Nutritonal Sciences, Cornell 
University 
 
What the study is about:  
Choline, a nutrient found in the diet (i.e., eggs, nuts, and beef), was 
recently recognized as a required nutrient for humans.  The recommended 
dietary intake level for pregnant women is 450 mg/d. However, at present, 
it is not known whether this amount is optimal for pregnant women.  
Thus, this study seeks to assess the effect of pregnancy on choline status 
and to examine whether the current recommended dietary intake, 450 
mg/d, is enough to optimize choline status during pregnancy.   
 
Consent, Pregnant Women 
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There is evidence from animal studies that excess choline consumed by 
the mother during pregnancy may have long lasting beneficial effects on 
the memory and attention of the newborn.  However, no study has 
examined this in humans. Thus, this study seeks to assess the effect of 
extra choline (450 mg/d) for a total choline intake of 900 mg/d during 
pregnancy on learning, attention and memory in the infant.  The choline 
intake of 900 mg/d is an amount that can be obtained by the diet and is 
well below the upper level of tolerance, 3500 mg/d. 
 
There is evidence that choline status affects folate (another essential 
nutrient) and vice versa.  Thus, this study seeks to examine the 
relationship between choline and folate status.
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What we will ask you to do:   
Screening Phase: 
First, it is necessary to determine whether you meet the inclusion criteria 
of this study.  This process will take up to 1 hour.  The inclusion criteria 
are as follows:   
 I am pregnant  (non-pregnant women are also eligible for the study 
in order to provide us with a control group) 
 I have not entered my third trimester (i.e., wk 27) 
 I am between 21 and 40 years of age. 
 I eat meat and other animal products 
 I am not a current smoker. 
 I am not using recreational drugs  
 I am not drinking alcoholic beverages  
 I am healthy 
 I do not have gestational diabetes 
 I do not have anemia. 
 I do not have kidney or liver problems. 
 I am not chronically taking medication that affects liver function. 
 I had a body mass index (BMI) < 34 as my pre-pregnancy weight 
During the screening phase, you will have your blood drawn (~ 4 
tablespoons) which will be used to assess your health status and measure 
select vitamins/nutrients.  DNA will also be obtained from your blood in 
order to investigate the effect of nutrients for people of different genetic 
make-up.  You will also complete a health history questionnaire.   
 
Dietary Intervention Phase  
If you meet the required criteria, you will be invited to participate in a 
twelve week feeding study.  Throughout this study you will consume a 
normal mixed diet consisting of breakfast, lunch, dinner and snacks.  You 
will consume at least one meal per day (breakfast, lunch or dinner) in the 
human metabolic research unit located at Cornell University.  The other 
meals will be provided as takeout meals.  You will also consume a 
 152 
 
prenatal vitamin/mineral supplement to ensure that you are meeting the 
recommended dietary intake levels for pregnant women of all the essential 
nutrients.  In addition, you will be randomized to a choline supplement to 
achieve total choline intakes of 450 or 900 mg/d.  To increase the study’s 
validity, the level of choline intake to which you are assigned (i.e., 450 or 
900 mg/d) will not be disclosed.  
 
To help us better understand choline requirements and use during 
pregnancy, a small portion of the choline will be labeled from week 6 to 
12.  This label (marker) is safe and has been used many times in studies 
involving babies, young children and pregnant women.  
 
It is important that you eat all of the food that we give you and that you 
eat nothing else outside of the study food. You will be weighed every 
week and extra food/beverages will be provided as necessary to ensure 
appropriate weight gain (~ 1 pound per week).   
 
Blood will be taken by a trained phlebotomist (i.e., a person that is trained 
to draw blood) before the start of the study and at weeks 3, 6, 9, 10 and 
12.  The blood will be used to analyze how choline intake, folate intake 
and/or pregnancy influences biomarkers of status. Also we will use the 
DNA obtained from the blood to analyze how genetic differences 
influence the use of choline and/or folate.  In addition, you will be 
required to collect your urine over a 24 hour period at the beginning of the 
study (week 0) and at weeks 6, 9, and 12.   
 
Time Between End of Dietary Intervention Phase and Delivery 
We request that you continue on the choline supplement that you 
consumed during the intervention study (ie, 100 or 500 mg/d) until you 
delivery the baby.  This is an estimated time of 1 week.  We will provide 
the choline supplement on a weekly basis. 
 
At Delivery 
We intend to obtain a final blood sample from you and from the umbilical 
cord when you deliver the baby.  This blood will be used to measure your 
choline and folate status as well as that of the baby (i.e., umbilical cord).  
We will also use the cord blood to extract DNA to provide information on 
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the influence of genetic differences on choline/folate status in your baby. 
In addition, we intend to retain the placenta which is normally discarded 
after the delivery of your baby.  Your placenta will be used to examine 
how choline intake influences the expression of relevant genes as well as 
choline utilization.  Lastly, we intend to ask you a few questions (i.e., less 
than 5 minutes of your time) about your delivery and the baby’s height 
and weight (included in your informational packet).   
 
Samples obtained during your participation on this study may be used by 
the investigators (or collaborators) for the purposes of learning more 
about other nutrients (ie., vitamin D and biotin) and how genetic 
differences affect requirements for these nutrients. 
It is possible that other investigators will have access to your blood samples 
(including DNA), placental tissue, and urine samples; however, the samples will be 
de-identified (ie, no names will be used). 
 
Cognitive Testing of Infant 
We would like to perform cognitive tests that assess your infant’s 
attention and memory when he/she is three, six, nine and twelve months 
of age.  These tests will measure your child’s eye movements to changes 
in pictures/images. Feeding your baby between tests is fine.  These tests 
are non-invasive. Each test is approximately 5-10 minute and will take up 
to 30 minutes total.
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Risks and benefits:  
We foresee minimal risks as part of your participation in this study. The 
choline dosage of 450 mg/d is the recommended amount for pregnant 
women and is considered to be adequate. The choline dosage of 900 mg/d 
is considered to be safe (Institute of Medicine, National Academy of 
Science) and falls within the range of choline intake consumed by the 
general population.  None-the-less, we will monitor your health status as 
you progress through this study.  Specifically we will  obtain a blood 
chemistry profile and a complete blood count at weeks 0, 3, 6, 9 and 12.  
These tests provide information on your blood lipids, liver and kidney 
function, and iron status.  We will also take your blood pressure on a 
weekly basis. Should any problems be identified, we will refer you to your 
physician who will advise on your continuing to participate in this study.  
 
 
As with any blood draw, it is also possible that you will experience some 
dizziness, ill-feeling and bruising during/after the blood draw.  In 
addition, having blood samples taken always includes a certain low risk of 
infection.  To minimize this risk,  blood will be drawn by a trained 
phlebotomist at the human metabolic research unit while you are lying 
down.   
 
 
There are no established direct benefits to you or your baby. From this 
study we hope to draw conclusions regarding the optimal intake levels of 
choline and folate in pregnant women, potentially benefiting the health of 
other women and children. 
 
In the event that you should be injured in the course of this research study, 
you will be provided with necessary medical care in Cayuga Medical 
Center At Ithaca.  This statement does not mean that either such medical 
care or hospitalization, if necessary, will be free of charge. 
 
Compensation:  
Week of Study Payment 
1 $50 
2 $60 
3 $70 
4 $80 
5 $100 
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6 $120 
7 $140 
8 $160 
9 $180 
10 $200 
11 $220 
12 $240 
 
You will be paid the dollar amounts indicated above in two allotments 
($480 at week 6 and $1140 at week 12) for a total of $1620. Should you 
stop participating in the study, you will be compensated for the time you 
have spent on the study.   
 
You will also be compensated for the blood and information obtained at 
delivery ($100) and for each cognitive evaluation session ($50 per session 
x 4 sessions for a total of $200).   
 
Taking part is voluntary:  
Your participation in this study is completely voluntary. If you decide to 
take part, you are free to withdraw at any time; however you will not be 
eligible to receive monetary compensation after ending the study.  You 
will be able to keep the money you have earned up to that point.  
The results of your blood tests, the genotyping and your child's 
cognitive tests will be kept confidential.  
In any sort of report we make public, we will not include any information 
that will make it possible to identify you. Research records will be kept in 
a locked file; only the researchers will have access to the records. We will 
need to videotape the infant’s face in order to analyze reaction times based 
on the infant’s eye movements.  Only the researchers will have access to 
the videotape.  Upon the conclusion of the data analysis, the videotape 
will be destroyed (by September 2015). 
 
If you have questions: The main researcher conducting this study is 
Professor Marie Caudill. Please ask any questions you have now. If you 
have questions later, you may contact Marie Caudill at 
mac379@cornell.edu or at 607-254-7456.  Should you contact Professor 
Caudill via email, please be aware that there is a chance that your answers could be 
read by a third party as internet and email transmissions are neither private or secure. 
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If you have any questions or concerns regarding your rights as a subject in 
this study, you may contact the Institutional Review Board (IRB) for 
human study participants at 607-255-5138 or access their website at 
http://www.irb.cornell.edu. You may also report your concerns or 
complaints anonymously through Ethicspoint or by calling toll free at 1-
866-293-3077. Ethicspoint is an independent organization that serves as a 
liaison between the University and the person bringing the complaint so 
that anonymity can be ensured. 
 
You will be given a copy of this form to keep for your records.   
 
Statement of Consent: I have read the above information, and have 
received answers to any questions I asked. I consent to take part in the 
study.  
 
Your Signature ______________________________ Date ______ 
Study Representative Signature __________________ Date_______ 
 
In addition to agreeing to participate, I also consent to having my child's 
cognitive function assessed and to having these activities videotaped 
during the session. 
 
Your Signature ________________________________  Date ________ 
Study Representative Signature ___________________ Date ________ 
 
This consent form will be kept by the researcher for at least five years 
beyond the end of the study and was approved by University of Cornell’s 
Institutional Review Board for Use of Human Study Participants  on June 
5 2008 and by Cayuga’s Medical Center’s Review Board for Use of 
Human Study Participants on October 16, 2008. 
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Cornell University  
Informed Consent for Research Involving Human Study Participants 
 
You are being invited to participate in a research study. This form is 
designed to provide you with information about this study. The Principal 
Investigator or representative will describe this study to you and answer 
any of your questions.   
 
Project Title:  
Effect of maternal choline intake on maternal/fetal biomarkers of choline 
status  
 
Investigators: 
Marie Caudill, PhD, RD; Associate Professor, Division of Nutritional Sciences, 
Cornell University 
Eva Pressman, MD. Director of Obstetrics and Maternal-Fetal Medicine, Department 
of Obstetrics and Gynecology, University of Rochester School of Medicine, 
Rochester, New York 
Richard Canfield, PhD. Research Associate, Division of Nutritional Sciences, Cornell 
University 
Barbara Strupp, PhD. Professor, Division of Nutritional Sciences, Cornell University 
Srisatish Devapatla, MD. Director, Special Care Nursery, Chairman- Dept. of 
Pediatrics, Cayuga Medical Center at Ithaca, Ithaca, New York. 
Sandy Saintonge, MD. Assistant Professor of Clinical Public Health and Clinical 
Pediatrics, Weill Cornell Medical College, Attending Physician, New York Hospital 
Queens, Department of Emergency Medicine 
Cydne Perry, PhD. Postdoctoral Research Associate, Division of Nutritonal Sciences, 
Cornell University 
 
What the study is about:  
Choline, a nutrient found in the diet (i.e., eggs, milk, and beef), was 
recently recognized as a required nutrient for humans.  However, at 
present, the amount of choline required during pregnancy and lactation is 
unknown.  Current dietary intakes in the general population range from ~ 
100 to 1000 mg/d with an average intake of 300 mg/d.   In 1998, an 
“Adequate Intake” level for choline of 425, 450 and 550 mg/d was 
established for non-pregnant, pregnant and lactating women respectively.  
Consent, Lactating Women 
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However, these estimates probably exceed actual requirements given that 
habitual choline intake levels in healthy populations are ~ 300 mg/d.         
 
There is evidence from animal studies that extra choline consumed by the 
mother during and after pregnancy may have long lasting beneficial 
effects on the memory and attention of the newborn.  However, no study 
has examined this in humans.  
 
Thus, this study seeks to examine choline metabolism (i.e., use) and 
requirements in pregnant and lactating women.  In addition, it seeks to 
assess whether higher choline intakes improve biomarkers of choline 
status (i.e., increase blood concentrations).   
 
Finally, there is evidence that choline status affects folate (another 
essential nutrient) and vice versa.  Thus, this study seeks to examine the 
relationship between choline and folate status.
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What we will ask you to do:   
Screening Phase: 
First, it is necessary to determine whether you meet the inclusion criteria 
of this study.  This process will take up to 1 hour.  The inclusion criteria 
are as follows:   
 I am a lactating mom who plans to exclusively breast feed for the 
duration of the study (ie, the next 10 weeks).   
 I can begin the feeding study at the start of my fifth week of 
lactation. 
 I am between 21 and 40 years of age. 
 I eat meat and other animal products. 
 I am not a current smoker. 
 I am not using recreational drugs.  
 I am not drinking alcoholic beverages.  
 I am healthy. 
 I do not have kidney or liver problems. 
 I am not chronically taking medication that affects liver function. 
During the screening phase, you will have your blood drawn (~ 4 
tablespoons) which will be used to assess your health status and measure 
select vitamins/nutrients.  DNA will also be obtained from your blood in 
order to investigate the effect of nutrients for people of different genetic 
make-up.  You will also complete a health history questionnaire.   
 
Dietary Intervention Phase  
If you meet the required criteria, you will be invited to participate in a ten 
week feeding study.  Throughout this study you will consume a normal 
mixed diet consisting of breakfast, lunch, dinner and snacks.  You will 
consume at least one meal every Monday, Wednesday, and Friday 
(breakfast, lunch or dinner) in the human metabolic research unit located 
at Cornell University.  The other meals will be provided as takeout meals.  
You will also consume a prenatal vitamin/mineral supplement to ensure 
that you are meeting the recommended dietary intake levels for lactating 
women of all the essential nutrients.   
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The study diet provides 350 mg/d choline and contains food  items that 
are significant sources of choline (i.e., eggs, beef, and milk).  In addition, 
you will be randomized to a choline supplement to achieve total choline 
intakes of 450 or 900 mg/d.  To increase the study’s validity, the level of 
choline intake to which you are assigned (i.e., 450 or 900 mg/d) will not 
be disclosed.  
 
To help us better understand choline requirements and use during 
lactation, a small portion of the choline will be labeled from study week 6 
to 10.  This label (marker) is safe and has been used many times in studies 
involving babies, young children and pregnant / lactating women.  
 
It is important that you eat all of the food that we give you and that you 
eat nothing else outside of the study food. You will be weighed every 
week and extra food/beverages will be provided as necessary to ensure 
that calorie needs are being met. 
 
Blood will be taken by a trained phlebotomist (i.e., a person that is trained 
to draw blood) before the start of the study and at weeks 3, 6, 9, and 10.  
The blood will be used to analyze how choline intake, folate intake and/or 
lactation influences biomarkers of status. Also we will use the DNA 
obtained from the blood to analyze how genetic differences influence the 
use of choline and/or folate.   
In addition, you will be required to collect your urine over a 24 hour 
period and to provide a breast milk sample at the beginning of the study 
(week 0) and at weeks 3, 6, 9 and 10.   The breast milk will be expressed 
completely from one breast (either right or left) at the beginning of the 
second feeding time (ie, 10 am).  All supplies/materials needed for this 
expression will be provided.  Samples obtained during your participation 
on this study may be used by the investigators (or collaborators) for the 
purposes of learning more about other nutrients (ie., vitamin D and biotin) 
and how genetic differences affect requirements for these nutrients. 
It is possible that other investigators will have access to your blood samples 
(including DNA) and urine samples; however, the samples will be de-identified (ie, no 
names will be used). 
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Cognitive Testing of Infant 
We would like to perform cognitive tests that assess your infant’s 
attention and memory when he/she is three, six, nine and twelve months 
of age.  These tests will measure your child’s eye movements to changes 
in pictures/images.  Feeding your baby between tests is fine.  These tests 
are non-invasive. Each test is approximately 5-10 minutes and will take 
up to 30 minutes total. 
Risks and benefits:  
We foresee minimal risks as part of your participation in this study.  
The choline dose of 450 mg/d is below the “adequate intake” level of 550 
mg/d; however, it is above the average intake level of 300 mg/d consumed 
by the general population.  In addition, the 450 mg/d choline intake level 
in this study is comprised of dietary choline obtained from a normal 
mixed diet (i.e., 350 mg/d) and supplemental choline (100 mg/d). The 
choline dosage of 900 mg/d is considered to be safe (Institute of 
Medicine, National Academy of Science) and falls within the upper 
range of choline intake consumed by the general population.  None-
the-less, we will monitor your health status as you progress through this 
study.  Specifically we will  obtain a blood chemistry profile and a 
complete blood count at weeks 0, 3, 6, 9 and 10.  These tests provide 
information on your blood lipids, liver and kidney function, and iron 
status.  We will also take your blood pressure on a weekly basis. Should 
any problems be identified, we will refer you to your physician who will 
advise on your continuing to participate in this study.  
 
 
As with any blood draw, it is also possible that you will experience 
some dizziness, ill-feeling and bruising during/after the blood draw.  
In addition, having blood samples taken always includes a certain low 
risk of infection.  To minimize this risk,  blood will be drawn by a 
trained phlebotomist at the human metabolic research unit while you 
are lying down.   
 
 
There are no established direct benefits to you or your baby. From this 
study we hope to draw conclusions regarding the optimal intake levels of 
choline and folate in lactating women, potentially benefiting the health of 
other women and children. 
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Compensation:  
Week of Study Payment 
1 $50 
2 $60 
3 $70 
4 $80 
5 $100 
6 $120 
7 $140 
8 $160 
9 $200 
10 $220 
 
You will be paid the dollar amounts indicated above in two allotments 
($360 at week 5 and $840 at week 10) for a total of $1200. Should you 
stop participating in the study, you will be compensated for the time you 
have spent on the study.   
 
You will also be compensated for each cognitive evaluation session ($50 
per session x 4 sessions for a total of $200).   
 
Taking part is voluntary:  
Your participation in this study is completely voluntary. If you decide to 
take part, you are free to withdraw at any time; however you will not be 
eligible to receive monetary compensation after ending the study.  You 
will be able to keep the money you have earned up to that point.  
The results of your blood tests, the genotyping and your child's 
cognitive tests will be kept confidential.  
In any sort of report we make public, we will not include any information 
that will make it possible to identify you. Research records will be kept in 
a locked file; only the researchers will have access to the records. We will 
need to videotape the infant’s face in order to analyze reaction times based 
on the infant’s eye movements.  Only the researchers will have access to 
the videotape.  Upon the conclusion of the data analysis, the videotape 
will be destroyed (by September 2015). 
 
If you have questions: The main researcher conducting this study is 
Professor Marie Caudill. Please ask any questions you have now. If you 
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have questions later, you may contact Marie Caudill at 
mac379@cornell.edu or at 607-254-7456.  Should you contact Professor 
Caudill via email, please be aware that there is a chance that your answers could be 
read by a third party as internet and email transmissions are neither private or secure. 
If you have any questions or concerns regarding your rights as a subject in 
this study, you may contact the Institutional Review Board (IRB) for 
human study participants at 607-255-5138 or access their website at 
http://www.irb.cornell.edu. You may also report your concerns or 
complaints anonymously through Ethicspoint or by calling toll free at 1-
866-293-3077. Ethicspoint is an independent organization that serves as a 
liaison between the University and the person bringing the complaint so 
that anonymity can be ensured. 
 
You will be given a copy of this form to keep for your records.   
 
Statement of Consent: I have read the above information, and have 
received answers to any questions I asked. I consent to take part in the 
study.  
 
Your Signature ________________________________ Date _______ 
Study Representative Signature ___________________ Date _______ 
 
In addition to agreeing to participate, I also consent to having my child's 
cognitive function assessed and to having these activities videotaped 
during the session. 
 
Your Signature ________________________________  Date _______ 
Study Representative Signature ___________________ Date ________ 
 
This consent form will be kept by the researcher for at least five years 
beyond the end of the study and was approved by University of Cornell’s 
Institutional Review Board for Use of Human Study Participants  on 
October 15, 2008. 
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Cornell University 
Informed Consent for Research Involving Human Study Participants 
 
You are being invited to participate in a research study. This form is 
designed to provide you with information about this study. The Principal 
Investigator or representative will describe this study to you and answer 
any of your questions.   
 
Project Title:  
Effect of maternal choline intake on maternal/fetal biomarkers of choline 
status  
 
Investigators: 
Marie Caudill, PhD, RD; Associate Professor, Division of Nutritional Sciences, 
Cornell University 
Eva Pressman, MD. Director of Obstetrics and Maternal-Fetal Medicine, Department 
of Obstetrics and Gynecology, University of Rochester School of Medicine, 
Rochester, New York 
Richard Canfield, PhD. Research Associate, Division of Nutritional Sciences, Cornell 
University 
Barbara Strupp, PhD. Professor, Division of Nutritional Sciences, Cornell University 
Srisatish Devapatla, MD. Director, Special Care Nursery, Chairman- Dept. of 
Pediatrics, Cayuga Medical Center at Ithaca, Ithaca, New York 
 
Sandy Saintonge, MD. Assistant Professor of Clinical Public Health and Clinical 
Pediatrics, Weill Cornell Medical College, Attending Physician, New York Hospital 
Queens, Department of Emergency Medicine 
Cydne Perry, PhD. Postdoctoral Research Associate, Division of Nutritonal Sciences, 
Cornell University 
 
What the study is about:  
This study seeks to provide data about nutrient requirements / utilization 
during pregnancy (see below).  You are being invited for possible 
participation in this study in order to examine choline requirements/use in 
non-pregnant women and to serve as a control for the pregnant women. 
 
Choline, a nutrient found in the diet, was recently recognized as a required 
nutrient for humans.  The recommended dietary intake level for non-
Consent, Nonpregnant Women 
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pregnant and pregnant women is 425 or 450 mg/d, respectively. However, 
at present, it is not known whether 450 mg/d is enough to maintain 
choline status in pregnant women.  Thus, this study seeks to assess the 
effect of pregnancy on choline status and to examine whether the current 
recommended dietary intake, 450 mg/d, is enough to maintain choline 
status during pregnancy. Your participation in this study will enable us to 
compare your choline status to that of a pregnant woman and in doing so 
assess the effect of pregnancy on choline status. 
 
It is possible that choline affects the use of folate, another essential 
nutrient and vice versa.    Thus, this study seeks to examine the 
relationship between choline and folate. 
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What we will ask you to do:   
Screening Phase: 
First, it is necessary to determine whether you meet the inclusion criteria 
of this study.  This process will take up to 1 hour.  The inclusion criteria 
are as follows:   
 I am not pregnant or lactating 
 I am between 21 and 40 years of age 
 I eat meat and other animal products 
 I am not a current smoker. 
 I am not using recreational drugs  
 I am willing to refrain from drinking alcoholic beverages during the 
12-week study period  
 I am healthy 
 I do not have anemia. 
 I do not have kidney or liver problems. 
 I am not chronically taking medication that affects liver function. 
 I have a body mass index (BMI) < 34 
During the screening phase, you will have your blood drawn (~ 4 
tablespoons) which will be used to assess your health status and measure 
select vitamins/nutrients.  DNA will also be obtained from your blood in 
order to investigate the effect of nutrients for people of different genetic 
make-up.  You will also complete a health history questionnaire. 
 
Study Phase  
If you meet the required criteria, you will be invited to participate in a 
twelve week feeding study.  Throughout this study you will consume a 
normal mixed diet consisting of breakfast, lunch, dinner and snacks.  You 
will consume at least one meal per day (breakfast or dinner) in the human 
metabolic research unit located at Cornell University.  The other meals 
will be provided as takeout meals.  You will also consume a customized 
vitamin/mineral supplement to ensure that you are meeting the 
recommended dietary levels for pregnant (and non-pregnant) women of 
all the essential nutrients.  In addition, you will be randomized to a 
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choline supplement to acheive total choline intakes of 450 or 900 mg/d.  
To increase the study’s validity, the level of choline intake to which you 
are assigned (i.e., 450 or 900 mg/d) will not be disclosed.   
To help us better understand choline requirements and use during 
pregnancy, a small portion of the choline or other relevant nutrients will 
be labeled from week 6 to 12.   This label (marker) is safe and has been 
used many times in studies involving babies, young children and pregnant 
women.  
 
It is important that you eat all of the food we give you and that you eat 
nothing outside what is provided. You will be weighed every week and 
your calorie intake will be modified to ensure that you do not lose or gain 
more than a couple of pounds. 
 
Blood will be taken by a trained phlebotomist before the start of the study 
and at weeks 3, 6, 9, 10 and 12.  The blood will be used to analyze how 
choline intake, folate intake and/or pregnancy influenced biomarkers of 
status. Also we will use the DNA obtained from the blood to analyze how 
changes in genes influence the use of choline and/or folate.  In addition, 
you will be required to collect your urine over a 24 hour period at the 
beginning of the study (week 0) and at weeks 6, 9, and 12.  Samples 
obtained during your participation on this study may be used by the 
investigators (or collaborators) for the purposes of learning more about 
other nutrients (ie., vitamin D and biotin) and how genetic differences 
affect requirements for these nutrients. 
It is possible that other investigators will have access to your blood (including DNA) 
and urine samples; however, the samples will be de-identified (ie, no names will be 
used). 
Risks and benefits:  
We foresee minimal risks as part of your participation in this study. All 
essential nutrients will be provided at or above the recommended intake 
level for non-pregnant women.  The choline dosage of 900 mg/d is 
considered safe (Institute of Medicine, National Academy of Science) and 
falls within the range of choline intake consumed by the general 
population.  
 
It is possible that you will experience some dizziness or ill-feeling during 
the blood draw.  In addition, having blood samples taken always includes 
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You will be paid the 
dollar amounts indicated 
above in two allotments 
($480 at week 6 and 
$1140 at week 12) for a 
total of $1620. Should you 
stop participating in the 
study, you will be 
compensated for the time 
you have spent on the 
study.   
a certain low risk of infection. To minimize this risk,  blood will be drawn 
by a trained phlebotomist at the human metabolic research unit while you 
are lying down.   
 
There are no established direct benefits to you. From this study we hope 
to draw conclusions regarding the optimal intake levels of choline and 
folate for pregnant women, potentially benefiting the health of other 
women and children. 
In the event that you should be injured in the course of this research study, 
you will be provided with necessary medical care in Cayuga Medical 
Center At Ithaca.  This statement does not mean that either such medical 
care or hospitalization, if necessary, will be free of charge. 
Compensation:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Taking part is voluntary:  
Participating in this study is completely voluntary. If you decide to take 
part, you are free to withdraw at any time; however you will not be 
eligible to receive monetary compensation after ending the study.  You 
will be able to keep the money you have earned up to that point.  
 
The results of your blood tests including the genotyping will be kept 
confidential.  
In any sort of report we make public, we will not include any information 
that will make it possible to identify you. Research records that contain 
Week of Study Payment 
1 $50 
2 $60 
3 $70 
4 $80 
5 $100 
6 $120 
7 $140 
8 $160 
9 $180 
10 $200 
11 $220 
12 $240 
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your name (i.e., informed consent, health history questionnaire, and the 
blood chemistry profiles and complete blood counts) will be kept in a 
locked filing cabinet in the office of the PI.  All other data (ie., blood 
measurements, DNA sequences) will be identified only by a code (i.e., 
number). 
 
If you have questions: The main researcher conducting this study is 
Professor Marie Caudill. Please ask any questions you have now. If you 
have questions later, you may contact Marie Caudill at  
mac379@cornell.edu or at 607-254-7456. Should you contact Professor Caudill 
via email, please be aware that there is a chance that your answers could be read by a 
third party as internet and email transmissions are neither private or secure. 
 
If you have any questions or concerns regarding your rights as a subject in 
this study, you may contact the Institutional Review Board (IRB) at 607-
255-5138 or access their website at http://www.irb.cornell.edu. You may 
also report your concerns or complaints anonymously through Ethicspoint 
or by calling toll free at 1-866-293-3077. Ethicspoint is an independent 
organization that serves as a liaison between the University and the person 
bringing the complaint so that anonymity can be ensured. 
 
You will be given a copy of this form to keep for your records. 
 
Statement of Consent: I have read the above information, and have 
received answers to any questions I asked. I consent to take part in the 
study.  
 
Your Signature ________________________________ Date ________ 
 
Study Representative Signature ___________________ Date ________ 
 
This consent form will be kept by the researcher for at least five years 
beyond the end of the study and was approved by University of Cornell’s 
Institutional Review Board for Use of Human Study Participants  on June 
5 2008 and by Cayuga Medical Center’s Review Board for Use of Human 
Study Participants on October 16 2008.
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Study Diet: Seven-day menu consumed by pregnant, lactating, and nonpregnant study participants
1 
Day Breakfast Lunch Dinner Folate content
2 
Monday Scrambled eggs (2 large) 
WW
3
 toast (2 slices) 
Peaches (1 snack cup) 
Pesto sandwich: 
WW
3
 bread (2 slices) 
Pesto (15 g) 
Swiss cheese (42 g) 
Romaine lettuce (20 g) 
Celery sticks (30 g) 
Carrot sticks (30 g) 
Beef and cheese tacos: 
Hard corn tortillas (3) 
Ground beef (80% lean; 105 g) 
Cheddar cheese (30 g) 
Sour cream (60 g) 
Salsa (90 g) 
Iceberg lettuce (20 g) 
Melon (112 g) 
Milk (10 oz) 
Breakfast-  133 µg 
Lunch-        101 µg 
Dinner-       125 µg 
Snack-          56 µg 
 
Total-         415 µg 
Tuesday Unenriched waffle (1) 
Hardboiled egg (1 large) 
Tuna sandwich: 
WW
3
 bread (2 slices) 
Tuna, canned (56 g) 
Cheddar cheese (30 g) 
Iceberg lettuce (30 g) 
Mayonnaise (15 g) 
Grapes (100 g) 
Spaghetti: 
Unenriched pasta (220 g) 
Tomato sauce (220 g) 
Mushrooms (30 g) 
Parmesan cheese (10 g) 
Mozzarella cheese (25 g) 
Milk (10 oz) 
Breakfast-    48 µg 
Lunch-        116 µg 
Dinner-         89 µg 
Snack-          56 µg 
 
Total-         308 µg 
Wednesday Wegman’s Fitness Crunch 
Cereal (80 g) 
Milk (10 oz) 
Raisins (1 box) 
Banana (1 medium) 
Pastrami sandwich: 
WW
3
 bread (2 slices) 
Pastrami (24 g) 
Swiss Cheese (23 g) 
Romaine lettuce (30 g) 
Cucumber slices (80 g) 
Vegetarian pizza: 
Unenriched dough (200 g) 
Tomato sauce (112 g) 
Roasted red peppers (60 g) 
Mushrooms (30 g) 
Spinach (20 g) 
Breakfast-  134 µg 
Lunch-       103 µg 
Dinner-      182 µg 
Snack-          56 µg 
 
Total-         475 µg 
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Mozzarella cheese (50 g) 
Apple sauce (1 snack cup) 
Milk (10 oz) 
Thursday Unenriched blueberry 
pancakes (2) 
Blueberries (25 g/pancake) 
Egg salad sandwich: 
WW
3
 bread (2 slices) 
Hardboiled egg (1 large) 
Mayonnaise (20 g) 
Romaine lettuce (45 g) 
Celery sticks (30 g) 
Carrot sticks (30 g) 
Beef and broccoli stir-fry: 
Steak beef (160 g) 
Broccoli (110 g) 
Un-enriched rice (200g) 
Onions (13 g) 
Melon (112 g) 
Milk (10 oz) 
Breakfast-    30 µg 
Lunch-       130 µg 
Dinner-       353 µg 
Snack-          56 µg 
 
Total-         569 µg 
Friday WW
3
 bagel (1) 
Mandarin oranges (1 snack 
cup) 
Bean burrito: 
WW
3
 flour tortilla (1)  
Black beans (40 g) 
Cheddar cheese (30 g) 
Un-enriched rice (30 g) 
Salsa (60 g) 
Sour cream (20 g) 
Lasagna: 
WW
3
 lasagna noodles (2) 
Tomato sauce (150 g) 
Ground beef (80% lean; 60 g) 
Cottage cheese (40 g) 
Mozzarella cheese (10 g) 
Parmesan cheese (10 g) 
Summer squash (40 g) 
Zucchini (40 g) 
Milk (10 oz) 
Breakfast-    74 µg 
Lunch-          46 µg 
Dinner-      122 µg 
Snack-          56 µg 
 
Total-         298 µg 
Saturday Un-enriched raspberry 
muffins (2) 
Banana (1 medium) 
Turkey sandwich: 
WW
3
 bread (2 slices) 
Turkey (25 g) 
Provolone cheese (23 g) 
Chicken quesadilla: 
WW
3
 flour tortillas (2) 
Chicken (65 g) 
Cheddar cheese (150 g) 
Breakfast-    68 µg 
Lunch-          62 µg 
Dinner-       201 µg 
Snack-          56 µg 
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Iceberg lettuce (20 g) 
Cucumber slices (80 g) 
Corn (100 g) 
Milk (10 oz) 
 
Total-         387 µg 
Sunday Granola cereal (80 g) 
Milk (10 oz) 
Raisins (1 box) 
Peaches (1 snack cup) 
Vegetable soup cup (1) 
Un-enriched corn muffin (1) 
Grapes (100 g) 
Goulash: 
Un-enriched pasta (200 g) 
Canned tomatoes (50 g) 
Tomato puree (100 g) 
Canned potatoes (35 g) 
Onion (30 g) 
Steak beef (120 g) 
Canned pineapple (70 g) 
Milk (10 oz) 
Breakfast-    47 µg 
Lunch-        109 µg 
Dinner-      162 µg 
Snack-          56 µg 
 
Total-         374 µg 
1
 Dietary folate was measured after trienzyme digestion with the microbiological assay as described in chapter 1 
2 
Daily snack included a low fat yogurt (vanilla, raspberry, or peach; 170 g) and a low-sodium V8 (5.5 oz) 
3 
WW, whole wheat 
173 
APPENDIX C: Publication authorizations 
Folate status response to a controlled folate intake among nonpregnant, pregnant, 
and lactating women ............................................................................................ 174 
Genetic variation: impact on folate (and choline) bioefficacy ............................ 175 
  
 174 
 
Folate status response to a controlled folate intake among nonpregnant, pregnant, 
and lactating women 
 A version of this manuscript was accepted for publication by The American 
Journal of Clinical Nutrition in June 2012 with the following authorship: Allyson A. 
West, Jian Yan, Cydne A. Perry, Xinyin Jiang, Olga V. Malysheva, and Marie A. 
Caudill, all of the Division of Nutritional Science at Cornell University. The American 
Journal of Clinical Nutrition Authors’ Statement and Copyright Release Form 
(http://www.ajcn.org/site/misc/Authors%27_Agreement_Form.pdf) authorizes the 
inclusion of the manuscript in this dissertation in the following section: 
Rights of Authors 
Effective upon acceptance for publication, ASN hereby licenses the following 
nonexclusive rights back to authors: 
a. Patent and trademark rights to any process or procedure described in the 
article 
b. The right to photocopy or make single electronic copies of the article for 
their own personal use, including for their own classroom use, or for the 
personal use of colleagues, provided the copies are not offered for sale and 
are not distributed in a systematic way outside of their employing institution 
(e.g. via an email list or public file server). Posting of the article on a secure 
network (not accessible to the public) within the author's institution is 
permitted. 
c. The right, subsequent to publication, to use the article or any part 
thereof free of charge in a printed compilation of works of their own, 
such as collected writings, theses, or lecture notes; to reuse original 
figures and tables in future works; to present data from the article at a 
meeting or conference; to include the article in their thesis or 
dissertation. 
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Genetic variation: impact on folate (and choline) bioefficacy 
 A version of this manuscript was published in the International Journal for 
Vitamin and Nutrition Research, 2010; 80:319-29, with the following authorship: 
Allyson A. West and Marie A. Caudill, both of the Division of Nutritional Science at 
Cornell University. E-mail correspondence with the editor of this journal shown below 
authorizes the inclusion of the manuscript in this dissertation.  
